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ABSTRACT
Particle-based vaccine delivery systems are under exploration to enhance antigen-specific
immunity against safe but poorly immunogenic polypeptide antigens. Chitosan is a promising
biomaterial for antigen encapsulation and delivery due to its ability to form nano- and
microparticles in mild aqueous conditions thus preserving the antigenicity of loaded
polypeptides. The objective of this work is to develop a chitosan particle based antigen delivery
system for enhanced vaccine response. Chitosan particle sizes, which ranged from 300 nm to 3
μm, were influenced by chitosan concentration, chitosan molecular weight and addition rate of
precipitant salt. The composition of precipitant salt played a significant role in particle formation
with upper Hofmeister series salts containing strongly hydrated anions yielding particles with a
low polydispersity index (PDI) while weaker anions resulted in aggregated particles with high
PDIs. Sonication power had minimal effect on mean particle size, however, it significantly
reduced polydispersity. Protein loading efficiencies in chitosan nano/microparticles, which
ranged from 14.3% to 99.2%, was inversely related to the hydration strength of precipitant salts,
and protein molecular weight and directly related to the concentration and molecular weight of
chitosan. Protein release rates increased with particle size and were generally inversely related to
protein molecular weight. In vitro studies showed that the uptake of antigen loaded chitosan
particles (AgCPs) by dendritic cells and macrophages was found to be dependent on particle
size, antigen concentration and exposure time. Flow cytometry analysis revealed that compared
to soluble antigen, uptake of AgCPs enhanced upregulation of surface activation markers on
APCs and increased the release of pro-inflammatory cytokines. Lastly, antigen-specific T cells
exhibited higher proliferative responses when stimulated with APCs activated with AgCPs
versus soluble antigen. These data suggest that encapsulation of antigens in chitosan particles

enhances uptake, activation and presentation by APCs with 1 µm mean particle size being
optimal. Similarly, in vivo studies showed that immunizing mice with AgCPs enhanced both
humoral and cell mediated immune response. Compared to PLGA nanoparticle and standard
alum adjuvants, AgCPs induced more potent humoral immune responses as evidenced by the
high total antigen specific IgG titer.
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1. BACKGROUND
1.1. Vaccines
A vaccine is a biological or chemical preparation used to develop immunity towards
disease causing organisms including bacteria, viruses, or autologous carcinogenic cells/tissue.
Vaccines mainly capitalize the immune system’s ability to respond rapidly to microorganisms
after a second encounter. As such, the goal of vaccination is to stimulate a strong, protective and
long-lasting immune response to the administered antigen. Based on the components of pathogen
used, vaccines are generally divided into three categories namely live whole pathogen vaccines,
subunit or inactivated vaccines, and deoxyribonucleic acid (DNA) vaccines. Live vaccine uses
active or partially inactivated microorganisms that can replicate in the host and can infect cells,
thereby functioning as an immunogen. A subunit vaccine includes only the specific parts of
pathogen that best stimulate the immune system but do not replicate in the host. In some cases,
these vaccines use epitopes—the very specific parts of the antigen that antibodies or T cells
recognize and bind to. A DNA vaccine gets transfected into human cells and directs the synthesis
of vaccine antigen in vivo.

1.1.1. Whole pathogen vaccines
The use of whole pathogen vaccines has led to some of the most spectacular
achievements in medical history. Some of the most deadly of diseases like small pox, measles,
mumps, rubella etc., have been nearly eradicated world-wide thanks to inexpensive live
attenuated vaccines. In the early days of vaccination live attenuated or inactivated pathogens
were used to generate a long-lasting immunity. These approaches in general, have been
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successful in inducing an immunogenic response including, antibodies, which neutralize viruses
or bacterial toxins, inhibit the binding of microorganisms to cells, or promote their uptake by
phagocytes [1]. Advantages of live bacterial vaccines include their mimicry of a natural
infection, intrinsic adjuvant properties and easy manufacturing and administration. Derivatives of
pathogenic and non-pathogenic bacteria or virus including influenza, smallpox, rotavirus etc., are
some of the routinely used live vaccines. However, pathogenic bacteria or viruses demands for
attenuation to weaken their virulence [2].
Increased immunological understanding and the development of molecular biology made
possible the development of new generation of live attenuated or inactivated pathogen vaccines
that can avoid the downsides of live vaccines [3]. These vaccines can be delivered orally or
nasally mimicking the route of entry of many pathogens and stimulate mucosal immune
response. Furthermore they can be designed to act as adjuvants to subunit antigens from a more
virulent or dangerous pathogen.
Even with latest advancements, attenuated or inactivated vaccines have been
unsuccessful against persistent pathogens inducing chronic infections including, Human
immunodeficiency virus (HIV) and hepatitis C virus (HCV) [4]. In such cases, induction of
potent and focused cell mediated immunity (CMI) will be necessary and may require the
induction of cytotoxic T lymphocytes (CTL), which kill host cells infected with intracellular
organisms. Unfortunately, non-living vaccines generally have proven ineffective at inducing
potent CMI responses. Although attenuated vaccines can induce CTL, they may still cause
disease in immune-suppressed individuals. Also, some pathogens are difficult or impossible to
grow in culture (e.g., HCV), making the development of live attenuated vaccines impossible. In

2

addition, many traditional live attenuated or inactivated vaccines based on whole bacterial cells
often contain components like endotoxins that can cause side effects and safety problems [5, 6].

1.1.2. Subunit vaccines
Subunit vaccines use a portion of the pathogen such as an individual protein as the
antigen. These vaccines are attractive because of their increased safety since they cannot revert
to a virulent form. The past decade, vaccine development has been shifting towards subunit
antigens including, recombinant protein subunits, synthetic peptides, protein polysaccharide
conjugates, and microbial DNA. Recent efforts have focused on developing conjugate vaccines
in which a weak antigen is linked to a stronger immunogen such as a protein or membrane
complex. The vaccine responsible for nearly eliminating HIB meningitis from infants and young
children is an example of a conjugate vaccine [7, 8]. DNA encoding pathogenic antigens have
been used as vaccines for veterinary use. They have also shown promise as vaccines in
preclinical studies against a wide variety of diseases including tuberculosis and HIV [9, 10].
In addition to being safer, subunit antigens are easier to manufacture and characterize.
However, subunit antigens are rapidly degraded by proteases and lack the immune stimulus, i.e.
co-stimulation and/or danger signals, often required for the generation of robust antigen-specific
immunity. As a result, a great deal of effort has been spent in evaluating delivery systems and/or
adjuvants capable of enhancing antigen delivery and providing the appropriate stimulus to
generate antigen-specific immunity [11, 12]. This is especially important when developing
vaccines for cancer using protein or peptide antigens that lack immune stimulus and degrade
rapidly in vivo [10, 13]. In contrast, a more immunogenic antigen may benefit from a specific
3

delivery vehicle that can influence the direction of the immune response. As such, adjuvants play
a major role in the development of modern vaccines.

1.1.3. Adjuvants
Adjuvants have traditionally been defined as agents added to vaccine formulations that
enhance the immunogenicity of antigens in vivo. An updated version of this definition divides
adjuvants into two classes: delivery systems and immunopotentiators, based on their dominant
mechanism of action [14]. Adjuvants can enhance the duration of immune response and reduce
the dose of antigen thus reducing the costs and toxicity. Also, adjuvants can be designed to elicit
required immune response including the modulation of antibody avidity, specificity, isotype or
subclass distribution, promoting antigen uptake by APCs, and stimulating CTLs [15]. Many of
the immunopotentiating adjuvants are sensed by various members of the Toll-like receptor
(TLR) family, a subclass of pathogen-recognition receptors [16]. Adjuvant delivery systems can
be used to protect subunit antigens and improve persistency. Along with protecting antigens,
delivery systems can be used for controlled and targeted delivery of antigen. Also, combinations
of delivery systems and immunopotentiating substances are being developed as multi-component
adjuvants with the potential to act synergistically to enhance the antigen-specific immune
response in vivo.
Until recently, the aluminum salt/gel-based (alum) adjuvants are the only ones contained
in vaccines licensed for human use in the United States with squalene-oil-water emulsion based
MF59TM being approved in European union [17]. Although alum has an excellent safety record,
comparative studies pitting alum to particulate adjuvants including virus like particles,
4

polymeric, and liposomal particles have shown that it is a poor adjuvant for humoral response
inducing comparatively lower antigen specific IgG antibodies. Also, alum has been shown to
induce Th2 rather than Th1 cytokine response resulting in weakened cell mediated response to
antigens [18]. As such, focus has shifted in the last decade towards the development of more
effective adjuvants constituting both immunopotentiating and delivery systems.

1.2. Immunopotentiators
1.2.1. Monophosphoryl lipid A (MPL)
MPL is a non-toxic component derived from lipopolysaccharide (LPS) of gram negative
Salmonella Minnesota bacterial cell wall. MPL is obtained by exposing the LPS to acid and base
hydrolysis sufficient to cause the loss of certain chemical groups. MPL retains
immunopotentiating properties of LPS but can be used safely in humans [19]. It is believed to
interact with TLR-2 and TLR-4 on APCs inducing a Th1-skewed response. MPL is thought to
directly activate macrophages resulting in the induction of IFN-γ and IL-2 [20]. However, it is
not as potent at inducing antibody responses compared to other adjuvants like QS21TM [20, 21].
As such, MPL has often been used in complex formulations, including liposomes, MF59 TM,
Alum, and QS21TM [15]. MPL is being looked into for use in cancer immunotherapy, infectious
disease vaccine, and treatment for allergies. MPL has been approved in Europe for use in
combination with allergy vaccines [22]. Also, MPL is among the few adjuvants approved by
Food & Drug administration (FDA) in recent history for use in HPV and H1N1 vaccines [23-25].

5

1.2.2. Unmethylated CpG dinucleotide motifs
CpG are small stands of DNA motifs consisting of an unmethylated CpG dinucleotide
flanked by two 5′ purines (optimally GpA) and two 3′ pyrimidines (optimally TpC or TpT).
CpG motifs are considered pathogen-associated molecular patterns (PAMPs) due to their
abundance in microbial genomes but are rare in mammalian genomes. Unmethylated CpG’s can
stimulate innate immune responses characterized by the production of antigen specific IgM,
IFNγ, IL-6, IL-12, IL-18 and TNFα [26]. The immune response to unmethylated CpG has been
linked in humans to the activation of TLR-9. Interactions with CpG results in the maturation of
dendritic cells, upregulation of MHC class II to produce professional antigen presenting cells,
induction of Th1 cytokines and triggering B-cell proliferation [27]. Studies have shown that CpG
motifs in the bacterial plasmid backbone of DNA vaccines contributed to vaccine
immunogenicity [28]. CpGs motifs are also being looked into as immunopotentiators for
antibody and cytokine production against protein based antigens including tumor antigens [29,
30].

1.2.3. Saponins
Saponins are steroid or triterpenoid glycosides found in wild or cultivated plants, lower
marine animals and some bacteria. Adjuvant activity of saponins is associated with branched
sugar chains or aldehyde groups or with an acyl residue bearing the aglycone [31]. Saponins
work by forming pores in cell membranes that allow antigens to gain access to the endogenous
presentation pathway resulting in antigen presentation by MHC class I and hence CTL activation
[32]. Saponin-based adjuvants have the ability to modulate the cell mediated immune system as
6

well as to enhance antibody production [33, 34]. They induce strong cytotoxic CD8+
lymphocyte responses and potentiate the response to mucosal antigens. Also, saponins have been
shown to induce cytokines such as, IL-2, and INF-γ that can induce a strong Th1 response [31].
Saponins extracted from the bark of Quillaja saponaria tree bark have shown great
promise and are the most studied for use as adjuvants. A highly purified fraction called QS21TM
is a potent adjuvant for the induction of a Th1- response, including CTLs and IgG2a antibody
secretion [32, 34]. A number of clinical trials are underway using QS21 as adjuvant for cancer
vaccines (melanoma, breast, and prostate) and infectious diseases (HIV, malaria, and hepatitis B)
[35, 36].

1.2.4. Cytokines
All immunopotentiating adjuvants induce cytokine production. Cytokines are key
immunomodulators during the development of an adaptive immune response. Therefore, it
makes sense to incorporate recombinant cytokines directly into vaccine formulations. As such,
cytokines are being evaluated as adjuvants instead of cytokine inducing adjuvants. The cytokines
that have been evaluated most extensively as adjuvants include IL-1, IL-2, IFN-γ, IL-12 and
granulocyte-macrophage colony-stimulating factor (GM-CSF) [37]. IL-6, IL-1, and IL-12 which
promote both humoral and cell mediated responses are being used in mucosal or nasal vaccines
for viral and bacterial infections including HIV [38, 39]. However, cytokines are dangerous at
high levels in circulation. Systemic exposure to pro-inflammatory cytokines can induce systemic
toxicity, chronic inflammation, and infections in immune compromised patients [37]. Also,
cytokines have low in vivo half-life and are relatively expensive. Nevertheless, considerable
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progress has been made in the use of cytokines for the immunotherapy of cancer. Cytokines like
GM-CSF IL-2 and IL-12 in combination with other adjuvants or particulate carriers are being
used in cancer immunotherapy and viral vaccines [40, 41].
Other classes of immunopotentiating adjuvants include viral vectors, virus like particles,
and immunostimulatory complexes. However these adjuvants are also classified as antigen
delivery systems and are covered in the following sections.

1.3. Antigen delivery systems
Antigen presenting cells (APCs) like dendritic cells (DCs) play a crucial role in initiating
T-cell-mediated immunity. They can control a substantial part of the adaptive immune response
by internalizing and processing antigens through major histocompatibility complex (MHC) class
I and class II pathways, presenting antigenic peptide complexes with MHC I and MHC II to
CD4+ and CD8+ T lymphocytes, and producing cytokines. Therefore, targeting APCs with an
antigen delivery system provides tremendous potential in developing new vaccines. Particles
with size similar to that of pathogens the immune system has evolved to combat can be
efficiently internalized by APCs. The uptake of particles of sizes <5µm by phagocytic cells has
been well documented and uptake into APC is likely to be important in the ability of particles to
perform as vaccine adjuvants. It has been reported that macrophages carry antigens within the
microparticles to lymph nodes and differentiate into dendritic cells (DC) [42]. In addition, uptake
of nano/micro particles encapsulating antigens by APC's including DC's, macrophages, and Bcells has been demonstrated. The appropriate size for particulate carriers appears to be in the
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range of 1–3µm [43, 44], and it appears that cationic particles are particularly effective for
uptake into macrophages and DC [45].
Particulate carriers can be modulated to present multiple copies of antigens on their
surface, which has been shown to be optimal for B cell activation. It has been demonstrated that
organized arrays of antigens on surfaces are able to efficiently cross-link B cell receptors and
constitute a strong activation signal [46, 47]. In addition, particulate carriers can enhance the
persistence of antigens by protecting them from degradation. Recent studies showed that,
together with the activation of innate immunity, the duration of antigen persistence is important
in triggering protective T cell responses [48]. Finally, immunopotentiators may be included in
particulate delivery systems to enhance immune responses by focusing effects on the APC and to
limit the potential for adverse events by restricting their systemic distribution to the injection
site. Given the advantages of particulate carriers, a myriad of particulate platforms including
viral carriers, liposomes, immunostimulatory complexes (ISCOM), proteasomes, polysaccharide,
and polymeric particles are being developed for vaccine delivery. However, only the
Recombinant Human Papillomavirus bivalent (Hep B) vaccine that employs virus like particles
(VLP) for antigen delivery has been approved by the FDA for use in humans [49-51]. Particulate
antigen carrier’s lack of success can be attributed to the complexity of particulate systems that
requires extensive studies for approval. As such, there is a need to develop a simple particulate
system that can be customized to deliver antigens/immunopotentiators to various immune
modalities. We will further review the different types of particle antigen delivery/adjuvant
systems below.
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1.3.1. Viral vectors
Viral vectors make use of this natural immunogenicity of viruses to develop vaccine
response towards the embedded antigens making them ideal for antigen delivery. Viral vector
vaccines consist of replicating or non-replicating viruses that carry defined genetic material from
the pathogen (Figure 1). Viral vector vaccine is essentially a combination of DNA and live
attenuated vaccines. Viral vector vaccines transfect DNA into host cell for production of
antigenic proteins that can be tailored to stimulate a range of immune responses, humoral or cell
mediated response (CD4, CTL, and CD8) [52].
Viral vector vaccines, unlike DNA vaccines, can be tailored to actively invade host cells
and replicate, much like a live attenuated vaccine, further activating the immune system like an
adjuvant. Adenovirus is the most frequently used vector platform being evaluated for vaccines
against Alzheimer’s disease, Malaria, Influenza, Tetanus, and HIV [53, 54]. Other vectors that
have shown success include modified vaccinia virus Ankara (MVA) and canarypox vector [54].

1.3.2. Virus like particles
Virus like particles (VLP) are self-assembling non-infective viral protein envelopes
without any viral genetic materials (Figure 2). The protein envelopes are used as platforms to
deliver components of pathogenic virus or bacteria that are attached or inserted into the particle
depots [55]. VLPs like viral vectors can be designed to elicit strong humoral and cell mediated
immune responses.
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Several recombinant VLP vaccines are at different stages of clinical trials including
RecombivaxTM (Merck) and Engerix-BTM (GSK), which are composed of the viral small
envelope protein, which upon expression in yeast formed VLPs [56]. While these were effective
at delivering the antigens, they suffered from a lack of immunogenicity. However, an updated
version consisting of Pre-S1, Pre-S2, and HBV surface antigens elicited a strong antibody
response [57]. The most recently approved VLP vaccine is GardasilTM for immunization against
HPV and subsequent prevention of cervical cancer and genital warts. This vaccine is composed
primarily of self-assembled particles of L1 protein from HPV encompassing alum and has been
shown to reduce infection by up to 90% [58]. Additionally, a malaria vaccine composed of a
VLP of HBV core antigen containing proteins from the circumsporozoit stage of the Plasmodium
parasite was shown to produce significant humoral and cellular immune responses when
formulated with AlhydrogelTM [59]. Other VLP based vaccines in preclinical studies include
vaccines for influenza, hepatitis C virus (HCV), Ebola virus, rotavirus and SARS [56].

1.3.3. Liposomes
Liposomes are self-assembling particles constituting phospholipid bilayer shell with an
aqueous core [60]. They can be generated as either vesicles with single phospholipid bilayer
shell, or multilayered vesicles, that are made of several concentric phospholipid shells separated
by aqueous layers (Figure3) [61]. Multilayered liposomes can be used to delivery both antigens
and adjuvants. Antigens can either be encapsulated in the core of the liposome, buried within the
lipid bilayer or adsorbed on the surface for presentation to antigen presenting cells. Liposomes
are generally considered non-toxic given that the phospholipids are extracted from mammalian
11

sources. However, they are relatively non-immunogenic and are most useful as delivery agents
that can carry encapsulated antigen/adjuvant complexes for recognition and uptake by APCs
[62].
Liposomes can be made immunogenic by modifying the surface of the particle by adding
an immunopotentiating compound to the formulation [63]. Also, cationic liposomes have been
shown to aid in the development of cell mediated immune responses by facilitating uptake of
antigens by APCs [64]. Guan et al., showed that liposome-associated MUC1 peptide (BP25)
produced a strong specific CTL response and antibody response [65]. A lyophilized liposomal
formulation of BP25 lipopeptide, MPL and three lipids called L-BLP25 (StimuvaxTM, Merck)
had been shown to elicit a cancer antigen specific cellular immune response in patients with nonsmall-cell lung cancer [66]. Apart from StimuvaxTM which is in later stage 3 clinical trials for
lung and breast cancer, no major liposomal formulations are being evaluated for vaccine
delivery. This may be attributed to the use of organic solvents in liposome preparations that can
denature protein antigens, and instability of liposomes during storage resulting in limited shelf
life [67].

1.3.4. Immunostimulating complexes
Another vaccine delivery vehicle with potent adjuvant activity being studied in the clinic
is the immunostimulating complex (ISCOM). The cage-like particles encapsulating antigens
were produced by combining a protein antigen (preferable hydrophobic), cholesterol,
phospholipid and the saponin adjuvant Quil A (Figure 4) [68]. A similar vaccine delivery vehicle
and adjuvant has also been developed that uses the same material minus the antigen and is
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referred to as ISCOMATRIX. The antigen can be added later to the ISCOMATRIX during
formulation of the vaccine. This material seems to work similarly to ISCOMs, but provides for
more general applications by removing the requirement for hydrophobic antigens [68]. ISCOMs
carrying multiple copies of antigens are shown to be effectively internalized by APCs resulting
in cross presentation of antigens with both MHC-I and MHC-II [69].
A clinical study that compared a classical trivalent flu vaccine with an ISCOM adjuvant
version composed of the same three virus strains revealed a stronger immune response with the
ISCOM vaccine eliciting rapid antibody responses as well as CD4 + and CD8+ T-cell response
[70]. A separate study of an ISCOM based flu vaccine showed that virus-specific CTL memory
was achieved in 50–60% of the patients, compared to only 5% who received the standard flu
vaccine [71]. Additional ISCOM vaccines have been in clinical studies for HIV, herpes simplex
virus (HSV), HPV, HCV, and cancer [68, 72, 73]. Despite these successes, the actual use of
ISCOMs in human vaccines has been deterred by concerns regarding safety since some saponins
used in ISCOMs were shown to be toxic at elevated levels [74]. Nevertheless, certain saponins,
such as QuilA and QS-21TM have not shown major signs of toxicity in humans at the doses
administered [74].

1.3.5. Non-degradable particulate carriers
Non-degradable particles can vary from non-degradable polymeric particles (polystyrene,
latex, etc.,) to metallic/ceramic particles (gold, silica, magnetic oxide particles, etc.,) [75]. The
ability of non-degradable particles to remain in tissues for extended periods of time is meant to
help improve antigen persistence [55]. Gold and iron oxide particles have been frequently
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described for vaccine delivery usually to enhance the potency of DNA vaccines by improving
delivery into cellular interiors [76]. However, these results are obtained using electroporation. In
the absence of electroporation, the immunological effects of gold particle antigen carriers are
weak [77]. Also, recent studies show that the use of gold nanoparticles along with alum can
enhance the immune response against HBV, influenza, and malaria antigens [78]. Additionally,
vaccines using iron oxide particle delivery systems have been in clinical studies for blood stage
malaria [79].
Compared to metallic particles, polymeric particles have several technological
advantages including the ability to functionalize the particles surface to achieve effective
conjugation of antigens. Furthermore, when the antigen is covalently coupled to the particle, it
induced higher cellular and humoral responses when the antigen is absorbed [80]. Latex
particles, for example have been shown to increase the co-presentation of antigens with MHC-I
and MHC-II molecules by 1000-10,000 fold [81]. However, in general, non-degradable particles
are much less effective at cross-presenting antigens than degradable particles like chitosan based
antigen delivery systems [82]. Other disadvantages of non-degradable delivery systems include,
chronic inflammation, induration, pruritis, and cyst formation at the injection site [83].

1.3.6. Biodegradable polymeric particles
Biodegradable polymers provide sustained release of the encapsulated antigen and
degrade in the body to nontoxic, low molecular weight products that are easily eliminated [8486]. Polymeric biodegradable particles have considerable advantages over more traditional
antigen delivery systems including the controlled delivery of antigens and adjuvants to the
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desired location at predetermined rates and durations to generate an optimal immune response.
The carrier may also protect subunit antigens from degradation until they are released either
outside or inside the APCs [84]. Other potential advantages of the controlled delivery approach
include reduced systemic side effects and the possibility of co-encapsulating multiple antigenic
epitopes or both antigen and adjuvant in a single carrier.
Biodegradable polymeric nanoparticles or microparticles can be prepared from natural
polymers like proteins, polysaccharides or using synthetic biodegradable polymers. The selection
of the base material is based on various factors including but not restricted to size and antigen
properties (solubility, stability, size, etc.) [75]. Synthetic polymers such as poly (lactic acid)
(PLA), poly (lactide-co-glycolic acids) (PLGA), poly (methyl methacrylate) (PMMA), and poly
(ε-caprolactone) (PCL) have been developed for traditional drug delivery applications. Synthetic
polymer based particles enable better drug release kinetics compared to polysaccharide particles
as the former can provide drug release over a period of days to several weeks compared to the
quick release of the latter [87].
Polyesters including PLA, PLG, and PLGA are the most popular materials for the
preparation of polymer nanoparticle based antigen delivery systems [70]. These polymers have
been approved for use in humans (e.g., as sutures, bone implants and screws as well as implants
for sustained drug delivery) and have been extensively studied for subunit antigen delivery) [88,
89]. Studies have shown that PLGA particles can be loaded or functionalized with immunogenic
moieties that can target antigen presenting cells (APCs), eliciting the cellular and humoral
immune response that is several times superior to soluble antigen [90, 91]. Fredriksen et al. have
shown that PLGA and PLA microparticles delivering Atlantic salmon antigens induced an
elevated humoral response compared to soluble antigen alone [92]. Preclinical studies have
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shown that PLG nanoparticles can induce systemic antigen specific antibody titers comparable to
those of aluminum salts [88]. Additionally, a study using tetanus toxoid (TT) found that a
synergistic immune response could be achieved by injecting TT bound to an aluminum salt along
with TT-loaded nanoparticles [93]. Another study showed that PLG nanoparticles loaded with
MPL and a cancer-associated antigen (MUC1) were efficiently taken up by dendritic cells [94].
PCL nanoparticles together with mucoadhesive polysaccharide chitosan were used for delivering
Streptococcus equi surface proteins significantly increased the antigen specific serum IgG
antibody levels of vaccinated mice [95]. Studies showed that particles prepared from
Poly(gamma-glutamic acid) (γ-PGA) can activate human monocyte-derived dendritic cells and
strongly stimulate the production of chemokines and inflammatory cytokines as well as
upregulation of costimulatory molecules and immunomodulatory mediators involved in efficient
T cell priming. Furthermore, in vitro studies with DCs pulsed with allergen Phleum pratense
loaded γ-PGA nanoparticles showed an increase allergen-specific IL-10 production and
proliferation of autologous CD4+ memory T cells [96].
Despite obvious interest in nanoparticulate adjuvants and delivery systems, the use of
these polymers as peptide or protein delivery systems may negatively affect the stability of the
loaded compound due to the use of solvents in particle preparation and the acidic degradation
byproducts [94, 97, 98]. As such none of the polymer based vaccine delivery systems discussed
here have progressed beyond preclinical trials.
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1.4. Chitosan based antigen delivery systems
Chitosan is a natural polysaccharide obtained by alkaline deacetylation of chitin, a
principle component of shellfish exoskeleton [99, 100]. It is an unbranched copolymer of
glucosamine and N-acetylglucosamine units linked by α-glycosidic bonds (Figure 7). In solution,
chitosan’s primary amine groups become protonated and the polycationic charge facilitates cell
adhesion, uptake and interaction with various anionic proteins and peptides. The biological
properties of chitosan including biocompatibility, bioactivity, wound healing, and immune
system stimulation makes it suitable for biomedical applications including drug delivery, gene
delivery, wound healing, tissue engineering and vaccine delivery [101-106]. Finally, chitosan
has an excellent safety record in humans as a pharmaceutical excipient, a weight loss
supplement, an experimental mucosal adjuvant and in an FDA-approved hemostatic dressing
[107, 108].
Chitosan in different forms including solution, hydrogels, conjugates, and particles are
being used for various applications. Chitosan based delivery systems are being used for
molecular imaging, delivery of DNA, RNA, low molecular drugs, and protein therapeutics.
Chitosan’s mucoadhesive and absorption-enhancing properties have been extensively studied for
delivery of therapeutic proteins and antigens particularly via mucosal routes [109]. Chitosan can
interact with mucus and epithelial cells and induce a redistribution of cytoskeletal F-actin and the
tight junction protein ZO-1 resulting in opening of cellular tight junctions and increasing the
paracellular permeability of the epithelium [110, 111]. Also, chitosan charge and other structural
elements likely contribute to penetration-enhancing activity, since cationic polysaccharides, such
as quaternized diethyl aminoethyl (DEAE)-dextran were ineffective as an enhancer [112]. In
many studies, it has been demonstrated that chitosan-based formulations were superior in
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enhancing absorption of therapeutic proteins as well as induction of antibodies after mucosal
vaccination [113, 114]. While chitosan in different forms was used for vaccination, very few
studies involved the use of chitosan particles for vaccine and immunotherapy applications.
Chitosan micro/nanoparticulate systems are under intense investigation for drug, gene,
and protein delivery [115-119]. Chitosan particles have been manufactured via a variety of
chemistries including cross-linking, ionotropic gelation and precipitation-coacervation [120123]. The last two methods are particularly attractive for the delivery of labile peptides and
proteins because encapsulation is accomplished under mild, aqueous conditions. This is in
contrast to commonly used synthetic biomaterials that require organic solvents capable of
denaturing polypeptides and destroying bioactivity. Also, chitosan particles can be surface
functionalized with immunopotentiating compounds like LPS to mimic pathogens that elicits an
enhanced humoral and cell mediated immune response.
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HYPOTHESIS
The future of vaccine development has been clearly shifting towards particulate based
antigen delivery systems. The properties of chitosan along with its ability to actively encapsulate
labile polypeptides and peptides makes it ideal for delivery of antigens. Our laboratory’s
previous studies have shown that mixtures of recombinant cytokines or full-length protein
antigens in chitosan solution can enhance local retention and bioactivity following injection [41,
117, 124]. However, particles are naturally more immunogenic and may provide more robust
adaptive immunity than solution based formulations. Also, particle size can be optimized to
improve uptake by APCs, enhance APC activation, and antigen presentation. In this project we
explore the feasibility of chitosan particle based antigen delivery systems for enhanced antigen
specific immunity.
We hypothesize that protein antigens can be effectively encapsulated by chitosan
particles. The encapsulated antigens can then be taken by APCs resulting in APC activation.
Activated APCs would then present peptide antigen with both MHC-I and MHC-II to T-cells
resulting in robust antigen specific immunity. Also, the size of chitosan particles can be
optimized to attain enhanced immune response.
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APPROACH
Our research plan was to develop and evaluate chitosan particle based antigen delivery
platforms based on the direct encapsulation of antigens in chitosan particles. This strategy was
expected to hinder the in vivo dissemination of antigens through electrostatic immobilization on
and in chitosan molecules. In addition, highly cationic chitosan particles would adhere to
negatively charged extracellular matrix and cell membranes upon injection. This electrostatic
interaction would effectively anchor antigens at the injection site and allow their uptake by
APCs.
In this project, antigen-encapsulated chitosan particles (AgCPs) were developed and
evaluated as a novel antigen delivery system. In the first aim, AgCPs of mean sizes ranging from
300nm to 3µm were developed and characterized. The effect of formulation factors on particle
properties was evaluated. In the second aim, AgCPs of various sizes were evaluated in vitro for
their ability to enhance antigen presentation. Specifically, the effect of particle size on antigen
uptake by APCs was explored. Also, the ability of particulate antigens to induce APC activation/
maturation compared to that of soluble antigen was evaluated. The third and final aim evaluated
the ability of AgCPs to enhance antigen specific immune response in vivo.
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2. SPECIFIC AIM 1: Synthesis and Characterization of Chitosan Particles of Varying
Sizes- Effect of Formulation Factors on Particle Properties
2.1. Rationale
Chitosan is under investigation for a wide variety of biomedical applications including
drug delivery, gene delivery, wound healing, antimicrobial applications, tissue engineering and
vaccine delivery [101, 102, 104-106, 125]. The use of chitosan in these diverse applications is
supported by its exceptional versatility. Chitosan can be used in solutions, hydrogels and/or
nano/microparticles, while an endless array of chitosan derivatives with customized biochemical
properties can be prepared through facile conjugation of side chain moieties to solvent-accessible
amine and hydroxyl groups. As a result, chitosan is currently among the well-studied
biomaterials with more than 1800 publications in 2013 using chitosan as a keyword. For
reference, other ubiquitous biomaterials, polylactic-co-glycolic acid (PLGA) and
polycaprolactone (PCL) are keywords in only about 700 and 340 publications, respectively.
Chitosan nano/micoparticulate systems, in particular, are intensively studied for the
delivery of genes, protein biologics and antigens [116-119, 126, 127]. When developing
nano/microparticulate systems for drug/protein delivery applications it is important to be able to
control characteristics, such as particle size, size distribution, and surface charge, as these can
significantly influence release kinetics. For example, increasing particle size has been shown to
increase drug release rates of encapsulated drugs/proteins [128, 129]. In addition, particle size
has been shown to influence uptake by immune cells in vaccine applications. Particles with sizes
similar to pathogens, such as viruses (5-300 nm) and bacteria (1-5 µm), are readily taken up and
processed by antigen presenting cells (APCs) which leads to enhanced vaccine responses. Our
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recent studies demonstrated that 1 m chitosan particles were optimal for uptake by both
dendritic cells and macrophages, however, APC activation was highest with 300 nm chitosan
particles [127].
It is clear that different biomedical applications will require unique chitosan particles
with well-defined dimensions and release characteristics. Thus, there exists a need to develop a
methodology for effective control of chitosan particle size, protein loading efficiency and protein
release. Chitosan particles have been manufactured via a variety of chemistries including crosslinking, ionotropic gelation and precipitation-coacervation [120-123]. These last two methods are
particularly attractive for the delivery of labile polypeptides as encapsulation is accomplished
under mild aqueous conditions.
In this study, we utilized the precipitation-coacervation technique to comprehensively
characterize the effects of various formulation factors, such as chitosan concentration, precipitant
salt concentration, chitosan molecular weight, rate of precipitant addition, protein size and
sonication power on chitosan particle size, polydispersity, and protein loading efficiency. A
range of precipitant salts with varying strengths of hydration in the Hofmeister series were
explored. In vitro release studies were performed to determine the effect of particle size,
precipitant salt, and encapsulated protein on protein release from chitosan nano/microparticles.
An analysis of the binding between proteins and chitosan explains the impact of protein-chitosan
interactions during encapsulation and release. The results obtained in this study will be useful in
the standardization of protocols for the preparation of antigen encapsulating chitosan particles
(AgCPs).
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2.2. Methodology
2.2.1. Reagents
Chitosans with viscosities of 20, 20-200, 200-600, 600-1200, and 1200-2000 cPs, were
purchased from Primex (Siglufjordur, Iceland) and purified via filtration in hydrochloric acid and
precipitation in sodium hydroxide. Pluronic F-68, acetic acid, sodium chloride (NaCl), potassium
chloride (KCl), sodium sulfate (Na2SO4), ammonium sulfate ((NH4)2SO4), magnesium sulfate
(MgSO4), potassium sulfate (K2SO4), sodium citrate (Na3C6H5O7), trisodium phosphate
(Na3PO4), fluorescein isothiocyanate-labeled bovine serum albumin (FITC-BSA), unlabeled
BSA and ovalbumin (OVA) were purchased from Sigma (St. Louis, MO). FITC- OVA, FITCinsulin and FITC-concanavalin A (FITC-ConA) were purchased from Life Technologies (Green
Island, NY).

2.2.2. Preparation and characterization of chitosan particles
Chitosan particles were prepared using the precipitation-coacervation method developed
by Berthold et al., with slight modifications [130, 131]. In brief, chitosan was dissolved in a 2%
(v/v) acetic acid solution. Chitosan particles were formed by adding 50 mM precipitant salt
solution drop wise to the chitosan solution using an infusion pump (Pump 11 Elite, Harvard
Apparatus, Holliston, MA). Nonionic stabilizer Pluronic F-68 was added and particles were
allowed to stabilize for 2 hours under constant stirring and intermittent sonication using a
sonicator (S4000; Misonix Inc., Farmingdale, New York). Chitosan particles were collected after
centrifugation at 25,000 xg for 10 min at 4°C and freeze dried (FreeZone, Labconco, Kansas
City, MO) before further use. Chitosan particles loaded with various proteins including FITC23

BSA, FITC-Insulin, FITC-OVA, and FITC-ConA, were prepared in a similar manner except that
proteins were dissolved in chitosan solution before adding the precipitant salt solution. Size and
polydispersity index (PDI) of the resultant particles were determined by dynamic light scattering
(DLS) (Zetasizer, NanoZS90, Malvern). PDI was calculated as a value between 0 and 1 with the
value closer to 1 indicating highly poly dispersed particles and value closer to 0 indicating mono
dispersed sample.

2.2.3. Effect of formulation factors on particle properties
The influence of formulation factors, including chitosan concentration, molecular weight,
rate of precipitant addition, protein size, and sonication power, on chitosan particle size and size
distribution was determined. Preliminary experiments indicated that precipitant concentration,
stabilizer concentration, pH, and chitosan:protein ratio had negligible effect on chitosan particle
size (data not shown). Therefore, an experimental design using 6 factors including chitosan
concentration (0.5 to 5 mg/ml), chitosan viscosity (< 20 to 1200 cPs), precipitant salt
composition, infusion rate of precipitant (0.2 to 8 ml/min), sonication power (0 to 40 W), and
proteins of different sizes (insulin – (6 kDa), ovalbumin – (45 kDa), BSA – (66.5 kDa), and
ConA – (105 kDa)) was utilized. A constant chitosan-to-protein mass ratio of 10:1 was
maintained for all experiments. The experimental design is shown in Table 1.

2.2.4. Protein loading and release studies
Protein loading efficiency was calculated indirectly. Briefly, the amount of FITCconjugated protein remaining in the supernatant after removing the protein-loaded chitosan
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particles was determined via fluorescence spectroscopy. The difference between the initial and
the unencapsulated protein concentrations was divided by the initial concentration (equation 1).
Percentage loading efficiency =

(Initial conc−Unencapsulated conc)
Initial conc

× 100

(1)

For protein release studies, FITC-BSA loaded chitosan particles with discrete sizes (300
nm, 1 µm, and 3 µm) (see Table 2) and salt groups (Na2SO4, (NH4)2SO4, MgSO4, K2SO4, and
Na3C6H5O7) (see Table 3) were prepared using data gathered from previous experiments. FITCBSA loaded chitosan particles were suspended in deionized water or phosphate buffered saline
(PBS) and incubated in total darkness at 37ºC. To determine the effect of protein size on release
profile, chitosan particles loaded with different proteins, i.e. FITC-labeled insulin, OVA, BSA,
and ConA (see Table 4), were suspended in PBS and incubated at 37ºC. Supernatants were
collected and replaced by fresh deionized water or PBS at regular intervals for 2 weeks. Samples
were stored in the dark at -20ºC until batch analysis via fluorescence spectroscopy (excitation
wavelength: 490 nm, emission wavelength: 540 nm). Percent protein released was determined
by dividing the amount of released protein by total encapsulated protein.

2.2.5. Statistical analysis
All experiments were carried out in triplicate or quadruplicate. Where appropriate, data
are presented as means ± standard deviation. Where indicated, analysis of variance (ANOVA)
was performed using JMP software (SAS, Cary, NC). Statistical significance was accepted at the
p < 0.05 level.
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2.3. Results
2.3.1. Effect of precipitant salt type on chitosan particle properties
Preliminary studies indicated that salt concentration (above 100 mM), surfactant
(Pluronic F-68) concentration, and chitosan:protein ratio had negligible effect on chitosan
particle size, polydispersity and encapsulation efficiency. Therefore, subsequent experiments
focused on other factors such as chitosan concentration, chitosan molecular weight, precipitant
salt composition, precipitant salt addition rate, sonication power, and protein size. The viscosity
of chitosan was used as a surrogate for molecular weight as the two properties are related [132]
and molecular weight of polydisperse chitosan is not often reported.
To isolate the effect of precipitant salt composition, all other formulation parameters
were fixed. Chitosan concentration was kept at 1 mg/ml, chitosan viscosity was 200-600 cPs,
precipitant salt concentration was 100 mM, precipitant salt addition rate was 8 ml/min,
sonication power was maintained at 10 W, and FITC-BSA was used as a model protein.
Salts with anions and cations of varying hydration strength, according to the Hofmeister
series, were utilized. Sodium was used as a cationic constant while the effect of anion type was
explored. Likewise, sulfate was used as anionic constant while the effect of cation type was
investigated. As seen in Table 1, decreasing the hydrating strength of anionic component of
precipitant salt affected particle size. Specifically, sulfate and citrate anions with high degrees of
hydration induced the formation of 427 ± 5.5 nm to 490 ± 18.3 nm particles, respectively. As the
degree of hydration was reduced, through the phosphates, particle size increased from 427 ± 5.5
to 1621±188 nm. A further reduction in hydration strength to chloride anions was not able to
form particles. Changing the cationic component of the salt had less of an effect on particle size
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with sulfate salts of magnesium, sodium, and ammonium producing 445 ± 7.7 nm, 427 ± 7.6 nm,
and 550 ± 3.5 nm particles, respectively. In general, the PDI for all particles formed was between
0.11 to 0.15 except when Na3PO4 was used and PDI increased to 0.66 indicating a fairly poly
dispersed sample.
Increasing the hydration strength of the anionic component from phosphate to sulfate to
citrate resulted in marked increases in protein loading efficiencies from 14.68 ± 1.7% to 54 ±
2.6% to 83.7 ± 3.5%, respectively. Once again, changing the cationic component of the salt did
not significantly influence the protein loading efficiency. In fact, sulfate salts of sodium,
ammonium, and magnesium produced chitosan particles with protein loading efficiencies of 54 ±
2.6%, 62.5 ± 6.1%, and 47.5 ± 2.0%, respectively.

2.3.2. Effect of chitosan molecular weight and concentration on chitosan particle properties
To isolate the effect of the chitosan molecular weight, Na2SO4 was used as the precipitant
salt and all other formulation parameters were fixed as described above. Chitosan particle size
was found to be directly related to chitosan molecular weight, i.e. viscosity (Figure 8). Particle
sizes more than doubled, from 418 ± 16.2 nm to 854 ± 26.2 nm, by increasing the intrinsic
viscosity of chitosan from <20 cPs to 1200 – 2000 cPs (Table 1). In contrast, chitosan molecular
weight did not significantly influence protein loading efficiencies which were between 50.4 ±
2.3% to 58.5 ± 4.2% (Table 1).
To isolate the effect of the chitosan concentration, chitosan with viscosity of 20-200 cPs
was used, and all other formulation parameters were fixed as described above. Increasing
chitosan concentration from 0.5 mg/ml to 5 mg/ml resulted in particle size increasing from 334 ±
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27.5 nm to 656±10.6 nm (Figure 8, Table 1). Protein loading efficiencies were similar for 0.5,
1.0 and 2.0 mg/ml. However, when chitosan concentration was increased to 3 and 5 mg/ml, the
protein loading efficiency jumped to 73.6 ± 2.2% and 92 ± 0.8% respectively.

2.3.3. Effect of sonication on chitosan particle properties
To isolate the effect of sonication, Na2SO4 was used as the precipitant salt and all other
formulation parameters were fixed as describe above. Chitosan particles prepared using 10 W
sonication decreased in size to 438 ± 3.9 nm from 922 ± 79.2 nm without sonication (Figure 8).
PDI also decreased from 0.657 without sonication to 0.182 at 10 W (Table 1). Further increasing
sonication power to 40 W did not significantly affect particle size. However, PDI was further
reduced to 0.098 at 40 W (Table 1).
While increasing sonication power was effective in increasing particle uniformity, protein
loading efficiency was reduced. Loading efficiencies decreased from 92.3 ± 1.8% without
sonication, to 88.3 ± 5.3% at 10 W, to 74.2 ± 6.3% at 20 W, and 56.5 ± 2.6% at 40 W (Table 1).

2.3.4. Effect of salt addition rate on chitosan particle properties
To isolate the effect of salt addition rate, Na2SO4 was used as the precipitant salt and all
other formulation parameters were fixed as described above. Precipitant salt addition rate was
inversely related to chitosan particle size. Increasing the salt addition rate from 0.2 ml/min to 8
ml/min resulted in a decrease in particle size from 774 ± 33.23 nm to 424 ± 2.1 nm (Figure 8,
Table 1). Most of the size reduction was observed in the lower range of salt addition rates. In
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addition to becoming smaller, particles also became more uniform as PDI was reduced from
0.580 to 0.121.
Protein loading efficiency was also inversely related to precipitant salt addition rate.
Loading efficiencies decreased steadily from 71.9±7.0% at 0.2 ml/min, to 67.3±3.2 at 1 ml/min,
65.3±3.6% at 3 ml/min, 62±2.8% at 5 ml/min and 58.1±2.2% at 8 ml/min.

2.3.5. Effect of protein molecular weight on chitosan particle properties
A range of proteins, FITC-Insulin (6 kDa), FITC-OVA (45 kDa), FITC-BSA (66.5 kDa),
and FITC-ConA (105 kDa) were selected to study the effect of protein size on chitosan particle
properties. Na2SO4 was used as the precipitant salt while all other formulation parameters were
fixed as described above. The size of the encapsulated protein had no significant effect on
chitosan particle size (p>0.05). However, loading efficiencies decreased with increasing protein
molecular weight. Chitosan particles were loaded with FITC-Insulin, FITC-OVA, FITC-BSA,
and FITC-ConA at 98.3 ± 0.5%, 96.5 ± 1.1%, 58.1 ± 2.5%, and 53.5 ± 3.6% efficiency,
respectively (Table 1). Interestingly, even though the molecular weight of OVA is similar to
BSA, OVA was encapsulated by chitosan at a much higher efficiency than BSA.

2.3.6. Effect of release medium ionic strength on protein release
Chitosan and protein molecules are expected to bind electrostatically before and after
particle formation. As a result, exposure of particles to solutions with high concentrations of ions
is expected to disrupt electrostatic bonds and affect protein release. To explore the effect of
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release medium ionic strength on protein release, FITC-BSA encapsulated chitosan particles
formulated with Na2SO4 with mean size of 448 ± 12 nm and protein loading of 56.4 ± 6.3% were
exposed to increasing concentrations of PBS. Indeed, FITC-BSA release increased with ionic
strength of the releasing medium (Figure 9). Particles incubated in 0.1X, 0.5X, and 1X PBS
released 34.2%, 39.7%, and 45.2% of encapsulated FITC-BSA over a 1 week period. In contrast,
particles incubated with deionized water released only 2.6% of encapsulated protein.

2.3.7. Effect of chitosan particle size on protein release
To study the influence of particle size on protein release, FITC-BSA encapsulated
chitosan particles with nominal sizes of 300 nm, 1 µm, and 3 µm were generated based on the
results of Table 1. As seen in Figure 10, SEM pictures showed that the chitosan particles
obtained have spherical to elliptical morphology with good size distribution. The actual particle
sizes were 318.2 ± 11 nm, 1133 ± 54.1 nm, and 2871 ± 216 nm (Table 2). FITC-BSA loading
efficiencies were 58.1 ± 3.7%, 83.5 ± 8.3%, and 96.6 ± 0.6%, respectively.
As seen in Figure 11, FITC-BSA release profiles from all particle sizes were
characterized by an initial burst of about 5-10% of the encapsulated protein followed by a slow,
sustained release in which a total of 30-50% of the protein was released in PBS over 1 week. The
amount of FITC-BSA released increased with increasing particle size. The “300 nm,” “1 µm,”
and “3 µm” groups released 31.4%, 42.6%, and 46.9% of their encapsulated FITC-BSA within
one week.
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2.3.8. Effect of precipitant salt on protein release
FITC-BSA encapsulated chitosan particles formulated with Na2SO4, (NH4)2SO4, MgSO4,
Na3C6H5O7, and Na3PO4 yielded particles of sizes 448 ± 12 nm, 561 ± 3.4 nm, 462 ± 6.3 nm, 478
± 64.3 nm, and 1423 ± 156 nm respectively, with protein loading efficiency of 56.4 ± 6.3%, 62 ±
5.3%, 54.3 ± 3.4%, 86 ± 2.1%, and 14.3 ± 6.6%, respectively.
Protein release profiles of particles were dependent on the cationic component of
precipitant salt with total amount protein release decreasing with decreasing hydrating strength
of cations. MgSO4, Na2SO4, and (NH4)2SO4 particles released 50.87%, 45.2%, and 31.7%
respectively over one week. However, changing the anion of the salt caused significant change in
protein release profile of the particles with Na3C6H5O7, Na2SO4, and Na3PO4 particles releasing
51.4%, 45.2%, and 98.1% of encapsulated protein over one week.

2.3.9. Effect of encapsulated protein on protein release
Chitosan particles precipitated with Na2SO4 and loaded with FITC-insulin, FITC-OVA,
FITC-BSA, and FITC-ConA were similarly sized at 421 ± 10.1 nm, 429 ± 3.6 nm, 448 ± 22.4
nm, and 452 ± 5 nm, respectively (Table 4). Protein loading efficiencies varied as before (Table
1) at 99.2 ± 0.1%, 98 ± 0.4%, 56.4 ± 3.2%, and 53.4 ± 1.8%, respectively.
As shown in Figure 12, the nature of encapsulated protein had a significant effect on
release kinetics. The two largest proteins, FITC-BSA and FITC-ConA, exhibited the highest
levels of burst and cumulative release, 48.2% and 48.9%, respectively, over a one week period.
The smallest protein, FITC-insulin, exhibited very little burst release but reached 40.42% release
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over one week. Interestingly, the vast majority of FITC-OVA remained in chitosan particles
after one week with only 2.4% released.

2.4. Discussion
There are several published methods for manufacturing drug or protein-loaded chitosan
particles [120-123]. Methods include the use of crosslinking agents [122, 133, 134], emulsionprecipitation [135], ionotropic gelation and precipitation-coacervation. The use of crosslinkers
or organic solvents during emulsion-precipitation can be detrimental when encapsulating labile
proteins. While both precipitation-coacervation and ionotropic gelation can form chitosan
particles in mild aqueous conditions, precipitation-coacervation was preferred for two reasons.
First, based on our own experiences, as well as published data, the size of chitosan particles on
any subsequent exploration of the effects of particle size in biomedical applications. Second,
ionotropic gelation generally results in lower drug/protein loading efficiencies with 38-72% of
BSA loading efficiencies observed with ionotropic gelation compared to 74-98% obtained with
precipitation coacervation method [40, 115].
In this study, we comprehensively explored the effects of 10 precipitation-coacervation
parameters on chitosan particle size, polydispersity, protein loading efficiency and protein
release. Four of the 10 parameters were eliminated in preliminary studies as having no impact.
The remaining 6 factors were studied individually by isolating a single parameter while fixing
the other 5 parameters.
Chitosan particle size was found to increase with chitosan concentration and molecular
weight/viscosity and decreased with precipitant salt addition rate and sonication power. The
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effect of chitosan concentration and molecular weight can be explained by the fact that addition
of increased amounts of the chitosan starting material to the precipitation-coacervation reaction
increases the probability of interaction of chitosan polymers to form larger particles. Conversely,
a higher salt addition rate reduced chitosan-chitosan and chitosan-protein interactions and led to
the formation of smaller sized particles. The effect of sonication was consistent with published
studies demonstrating that chitosan particles prepared through ionotropic gelation were reduced
in both size and PDI after sonication [114, 133, 134, 136]. Our data indicate that a threshold
level of sonication is preferred to produce a more uniform size distribution of chitosan particles,
but that further increases in sonication power adversely affected loading efficiency.
Protein loading efficiencies increased with chitosan concentration and molecular
weight/viscosity. These findings were consistent with previous studies demonstrating that drug
loading and release from chitosan particles was directly related to chitosan molecular
weight/viscosity [137]. Higher chitosan molecular weight and/or concentration increases the
likelihood of anionic proteins interacting with cationic chitosan molecules prior to precipitation.
In general, protein loading efficiencies decreased as protein molecular weight increased.
However, we also identified protein charge as a major factor in loading efficiency. Our findings
that protein release increased with ionic strength of the releasing medium (Figure 9) and that
NaCl disrupts protein-chitosan binding indicate that protein-chitosan binding is mediated via
electrostatic interactions. Therefore, a highly negatively charged protein, such as OVA, will be
loaded in cationic chitosan particles more efficiently and released more slowly than a similarly
sized protein with a more neutral or positive net charge.
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Among the strongest effects on chitosan-protein particle formation was the hydration
strength of precipitant salt anions. Strong Hofmeister series anions with high degrees of
hydration, such as citrate and sulfate, induced formation of smaller and more uniform particles.
Decreasing the degree of hydration by using phosphate anions resulted in an increase in both
particle size and polydispersity likely due to particle aggregation of weakly formed particles. A
further decrease down the Hofmeister classification to chloride anions abrogated particle
formation. These results were expected as salts with strongly hydrated ions can strip away water
molecules from proteins or biopolymers resulting in salting out or precipitation [138, 139].
Weaker ions such as Cl- are unable to remove a sufficient amount of water to induce
precipitation.
Interestingly, strong Hofmeister anions also induced higher loading efficiencies. It was
originally predicted that strong anions would independently disrupt chitosan-protein binding and
precipitate chitosan and protein. However, it appears that mixing chitosan and protein prior to
addition of precipitant salt allows sufficient electrostatic binding for the chitosan-protein
complexes to salt out together. Taken together with our particle size analysis, in general, strong
Hofmeister anions were better at forming highly loaded, chitosan-protein particles.
Release studies demonstrated that protein release from chitosan particles, regardless of
the sample group was characterized by an initial burst followed by sustained release. The release
was found to be strongly dependent on the releasing medium with 34.1-45.2% protein release
observed in PBS compared to that of 2.6% observed in deionized water. While previous studies
showed that the release of drug from chitosan particles was dependent on solution pH [40, 140],
our studies show that the release is also dependent on the ionic strength of the medium. ITC
studies showed that chitosan-protein binding was dependent on the salinity of solution.
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Specifically, chitosan-protein interaction was significant at 0mM NaCl, but was eliminated at 25
mM NaCl. In mildly acidic aqueous solutions, chitosan’s primary amines are protonated. Thus,
polycationic chitosan molecules interact electrostatically with co-formulated proteins. These
positive charges are likely to be responsible for electrostatic interactions with proteins. However,
when high levels of free anions, such as chlorides and phosphates, are present, they can interact
with the protonated chitosan and disrupt protein binding resulting in lower loading efficiencies
and/or faster release rates [130, 141].
Overall, smaller proteins were released from chitosan particles much more quickly.
However, OVA, despite being similar in size to BSA, was a notable exception. Only 2.4% of
OVA was released compared to 48.1% of BSA. This discrepancy can be explained by the higher
binding constant and free energy change of OVA versus BSA (Data not shown). In general,
proteins with higher densities of negative surface charges are likely to be loaded in chitosan
particles more efficiently and released more slowly. We are currently investigating the effects of
a protein’s charge density on its interactions with chitosan and other polysaccharides.
Finally, protein release rate was found to increase with particle size. Whether this effect
is driven by pore size, which we believe increases with particle size, is the subject of future
studies. Nevertheless, these data imply that one can customize protein release profiles through
manipulation of chitosan particle size

2.5. Conclusion
Different biomedical applications will require chitosan particles with specific dimensions
and release characteristics. The results of this study demonstrate that the properties of chitosan
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particles including size, size distribution, and protein loading can be effectively modulated by
controlling precipitation-coacervation formulation parameters. Understanding the influence of
these parameters will help standardize chitosan particle based delivery of proteins for continued
preclinical and clinical development. Furthermore, these data are valuable in engineering
controllable chitosan nano/microparticles for customized delivery of protein biologics and
vaccines. As such, the parameters were optimized to prepare chitosan particles of varying sizes
and were used in further studies.
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3. SPECIFIC AIM 2: Assess In Vitro Particulate Antigen Uptake and Presentation by
Antigen Presenting Cells
3.1. Rationale
Over the last several decades, vaccine development has shifted away from using
attenuated or inactivated whole pathogens in favor of recombinant subunit antigens [142-144].
This shift is partly due to safety concerns over potentially harmful pathogens and partly due to an
increasing interest in inducing immunity towards non-pathogenic self or self-like antigens such
as tumor-associated antigens or overexpressed proteins implicated in disease (e.g. amyloid beta)
[145-147]. While subunit antigens are much safer, they are also much less immunogenic than
whole pathogens. Subunit antigens are rapidly degraded by proteases and lack the requisite
secondary immune stimulus, i.e. co-stimulation and/or danger signals, required for the generation
of antigen-specific immunity [12]. As a result, a great deal of effort has been spent developing
delivery systems and/or adjuvants capable of enhancing vaccine responses to subunit and
polypeptide antigens [11, 12, 148].
The encapsulation of polypeptide antigens in nano- and/or microparticles has been
explored extensively as a strategy to enhance immunogenicity. The advantage of this strategy is
three-fold: First, encapsulation of antigens in particles can prevent antigen degradation and
enhance antigen persistence. Second, antigen presenting cells (APCs), such as macrophages and
dendritic cells, have been shown to readily phagocytose and process particles ranging in size
from 150 nm to 4.5 µm [149, 150]. Third, most particle-based platforms can be engineered to
contain additional adjuvants and/or targeting moieties to further influence immunogenicity [142,
143]. In general, antigens in particulate form have been shown to be more immunogenic than
their soluble counterparts [151, 152]. A myriad of particle-based antigen delivery approaches
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including liposomes, Immune stimulating complexes (ISCOMs), and polymeric particles are
under development and have been reviewed elsewhere [72, 142, 153].
Chitosan-based vaccine delivery systems have received increasing attention due to
chitosan’s remarkable versatility and unique characteristics [41, 51, 117, 124, 154-157].
Chitosan is a natural polysaccharide derived primarily from the exoskeletons of crustaceans.
Chitosan nano- and microparticles can be manufactured via either precipitation-coacervation
[158] or ionotropic gelation [153]. Polypeptides can be encapsulated either during particle
formation [40] or adsorbed to particle surfaces after formation [131]. Chitosan’s
mucoadhesiveness and ability to loosen epithelial gap junctions justifies its use in mucosal
vaccines. Several studies have shown that chitosan nano- and microparticles loaded with
antigens can generate mucosal immunity following intranasal vaccination [116, 159]. However,
chitosan particles are also expected to elicit robust immune responses via non-mucosal routes.
Yet, in the only s.c. vaccination study to date, no significant immunity was generated with a
vaccine comprised of ovalbumin (OVA) adsorbed to chitosan nanoparticles [131].
While the above study may have failed to induce immune activation due to a
documented change in antigen conformation, it is important to note that vaccine responses are
highly complex, involve multiple cell types and require successful completion of many
interdependent processes including antigen uptake, cytokine release, immune cell trafficking,
antigen presentation, co-stimulation, etc. To simplify the contributions of chitosan-based particles,
in this study, we focused solely on APC function. In particular, we evaluated the ability of antigenencapsulated chitosan particles (AgCPs) to enhance antigen uptake, APC activation and antigen
presentation. The effect of particle size on antigen uptake by both bone marrow-derived dendritic
cells and RAW 264.7 macrophages was quantified via spectrophotometry and flow cytometry.
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The ability of AgCPs to induce APC activation was determined by measuring upregulation of
surface activation markers as well as cytokine release. Finally, APCs exposed to AgCPs or soluble
antigens were compared for their ability to present antigen and induce proliferation of antigenspecific T cells.

3.2. Methodology
3.2.1. Reagents
Chitosan (viscosity 20-200, 200-600, and 600-1200 cPs degree of deacetylation 90%)
was purchased from Primex (Siglufjordur, Iceland) and purified via filtration in hydrochloric
acid and precipitation in sodium hydroxide. Pluronic F-68, acetic acid, sodium sulfate (Na2SO4),
FITC-BSA, OVA, L-glutamine, HEPES buffer, trypsin-EDTA, and lipopolysaccharide (LPS)
were purchased from Sigma (St.Louis, MO). Ammonium-Chloride-Potassium (ACK) lysing
buffer, Cell culture medium components including, fetal bovine serum (FBS), antibiotics,
Dulbecco's Modified Eagle Medium (DMEM), and RPMI-1640 medium were purchased from
Thermo Scientific (Rockford, IL). Recombinant murine granulocyte-macrophage colonystimulating factor (GM-CSF) was purchased from Peprotech (Rocky Hill, NJ) and OVA257-264
peptide were purchased from Thermo Scientific (Rockford, IL). All antibodies used for flow
cytometry along with cytometric bead array kits were purchased from BD Biosciences (San Jose,
CA).
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3.2.2. Mice
Female C57BL/6J, OT-1 and OT-II mice with respective CD4+ and CD8+ T-cells
expressing T-cell receptors specific to OVA protein peptides were purchased from The Jackson
Laboratory (Bar Harbor, ME). Mice were housed in a pathogen-free animal facility and used at
8 to 12 weeks of age. All experimental procedures were approved by the Institutional Animal
Care and Use Committee at the University of Arkansas and animal care was in compliance with
The Guide for Care and Use of Laboratory Animals (National Research Council).

3.2.3. Cell culture
RAW 264.7 mouse macrophage cells obtained from American Type Culture Collection
(Manassas, VA) were cultured in complete medium consisting of DMEM supplemented with
20% FBS and 1% penicillin/streptomycin. Bone marrow-derived dendritic cells (BMDCs) were
cultured from mouse bone marrow cells using an established protocol [160].

3.2.4. Preparation of AgCPs
Antigen encapsulating chitosan particles (AgCPs) were prepared via precipitationcoacervation as described previously with slight modifications [40, 131]. Briefly, chitosan was
dissolved in 2% acetic acid and passed through a 0.2 μm filter. AgCPs were formed by adding a
10% w/v sodium sulfate solution containing either FITC-BSA or OVA as model protein
antigens, henceforth referred to as BsaCPs or OvaCPs, respectively. Chitosan particles
containing no antigen (CPs) were formed in the same manner but without BSA or OVA.
Pluronic F-68 was added as a nonionic stabilizer and particles were stirred for 2 h with
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intermittent sonication (S4000, Misonix, Farmingdale, NY). Chitosan particles were separated
through centrifugation at 25,000 xg for 10 min and freeze dried before further use. Particles of
various sizes were obtained by varying formulation factors as seen in Table 2.

3.2.5. Characterization of AgCPs
Particle size and surface charge was measured via dynamic light scattering (DLS) (Nano
ZS90, Malvern Instruments, Malvern, UK). Morphological characteristics were documented
using scanning electron microscopy (SEM) (Nanolab 200, FEI, Hillsboro, OR). Briefly, AgCPs
dispersed in DI water were vacuum dried onto a glass slide. The sample slides are than sputter
coated with gold before examining under SEM. The encapsulation efficiency of FITC-BSA in
AgCPs was quantified via fluorescence spectroscopy (Synergy2, Biotek, Winooski, VT),
measuring the supernatant fluid after centrifugation. Antigen encapsulation efficiency was
calculated as seen in equation 2.
Antigen encapsulation efficiency=

(Initial antigen conc-Unencapsulated antigen conc)
Initial antigen conc

×100

(2)

3.2.6. Uptake of AgCPs by APCs
RAW 264.7 macrophages or BMDCs were collected and seeded at a density of 50,000
cells/well in 24 well plates. To determine the effect of particle size on uptake, cells were coincubated with of 300 nm, 1 µm, or 3 µm BsaCPs. To determine the effect of antigen
concentration on uptake, cells were co-incubated with BsaCPs at an effective antigen
concentration of 1, 5, 10, 20, or 30 µg/ml. To determine the effect of incubation time on uptake,
cells were co-incubated with 1µm BsaCPs at an effective antigen concentration of 30 µg/ml for
12, 24, or 48 h. After each co-incubation, cells were rinsed three times with PBS to remove
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particles not uptaken by cells. Cells were than lysed with 1% triton solution. The amount of
FITC-BSA released was quantified via fluorescence spectroscopy. To assess the percentage of
cells taking up BsaCPs, cells were rinsed three times with PBS and briefly trypsinized to form a
single cell suspension prior to analyzing on a FACSCantoII (BD Biosciences, San Jose, CA).

3.2.7. APC activation
Activation markers on macrophages and BMDCs co-cultured with AgCPs were analyzed
via flow cytometry. Briefly, RAW 264.7 macrophages and BMDCs were seeded onto 6 well
plates at a density of 1 x 106 cells/well and cultured in their respective growth medium for 24 h.
Medium containing BsaCPs was then added at a final antigen concentration of 30 µg/ml.
Unloaded 300nm CPs that contained no antigen were used at the same dry weight as 300nm
AgCPs. Medium alone was used as a negative control. After 24 h, cells were rinsed three times
with PBS and briefly trypsinized to form a single cell suspension. FcII and FcIII receptors were
blocked via incubation with 1 µg purified anti-mouse CD16/CD32 (clone: 2.4G2) per 1x106 cells
for 15 min on ice. Cells were stained for 30 min on ice with fluorescence-labeled mouse
monoclonal antibodies (1 µg/1x106 cells) to the following markers: MHC I (clone: AF6-88.5),
MHC II (clone: 2G9), CD11b (clone: M1/70), CD11c (clone: HL3), CD80 (clone: 16-10A1),
CD86 (clone: GL1), CD40 (clone: HM40-3) and CD53 (clone: 3E2). Cells were then washed
twice with cold PBS and analyzed on a six-color FACS CantoII. Data analysis was performed
using BD FACSDiva software (BD Biosciences, San Jose, CA).
Cytokines released from macrophages and BMDCs were quantified via cytometric bead
array (CBA) analysis. In brief, RAW 264.7 macrophages and BMDCs were seeded at 5 x 105
cells/well in 96 well plates. Cells were co-incubated with FITC-BSA alone or BsaCPs with
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approximate mean diameters of 300 nm, 1 µm or 3 µm. Once again, unloaded CPs and medium
alone were used as controls. After 72 h, culture supernatants were harvested to quantify
concentrations of inflammatory cytokines including, IL-1β, IL-6, TNF-α, MCP-1α, and MIP-1
with a customized CBA flex set (BD Biosciences, San Jose, CA). The multiplex beads were
read on a FACSCantoII and analyzed using FACP Array software (Soft Flow, Burnsville, MN).

3.2.8. Antigen presentation
The antigen presenting ability of BMDCs co-incubated with AgCPs was evaluated by
quantifying proliferation of Ag-specific T-cells. Briefly, BMDCs were seeded onto 6 well plates
at a density of 1 x 106 cells/well and cultured with OvaCPs with approximate mean diameters of
300 nm, 1 µm, or 3 µm at final antigen concentration of 10 µg/ml. BMDCs pulsed with peptide
OVA257-264 (SIINFEKL) or whole OVA protein, and unloaded CPs were used as positive and
negative controls, respectively. After 24 h, BMDCs were collected and co-cultured with CD8+ or
CD4+ T-cells isolated via negative selection using magnetic beads (Invitrogen, Grand Island,
NY) from the spleens of OT-I and OT-II mice, respectively. After 72 h of co-culture, T-cell
proliferation was assessed by the CellTiter-Glo (Promega, Madison, WI) cell proliferation assay.

3.2.9. Statistical Analysis
All particle characterization measurements, i.e. mean diameter, polydispersity index,
encapsulation efficiency and surface charge, are presented as mean ± standard deviation for 3
independent chitosan particle preparations. Antigen uptake, APC activation and cytokine release
experiments were carried out in triplicate. Antigen presentation experiments, which evaluated
the proliferation of antigen-specific T cells, were performed in duplicate. Student’s t-test was
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used to compare data from two groups of interest as indicated. For example, cytokine release
and T cell proliferation data in response to the soluble antigen treatment group and an AgCP
treatment group were compared. Analysis of variance was used to identify treatment-related
differences among the three different AgCP sizes. All statistical analyses were performed using
JMP software (SAS, Cary, NC). Significance was accepted at the p ≤ 0.05 level.

3.3. Results
3.3.1. Characterization of AgCPs
SEM images revealed that AgCPs were spherical to elliptical in shape with porous nonuniform structures (Figure 10). Formulation factors including chitosan concentration, sodium
sulfate addition rate, and sonication power were varied to generate AgCPs with nominal sizes of
300nm, 1µm, or 3µm. The measured mean diameters of these particles as determined by DLS
were 318 ± 11 nm, 1133 ± 54.1 nm, and 2871 ± 216 nm (Table 2). All preparations displayed a
unimodal size distribution (Figure 10) with modest polydispersity (Table 2). Antigen
encapsulation efficiencies were very reproducible and increased with particle size from 58.1 ±
3.7 % to 96.6 ± 0.6%. To determine the effect of antigen on particle size and charge, unloaded
CPs were prepared using the same conditions as the “300 nm” AgCPs except without antigen.
The mean diameter of CPs was slightly smaller than similarly prepared AgCPs – 289 ± 9 nm vs.
318.2 ± 11 nm. Also, the surface charge of CPs, +36.8 mV, was higher than the surface charge
of similarly sized AgCPs, +16.8 mV.
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3.3.2. Uptake of AgCPs by APCs
Uptake of AgCPs by APCs was found to depend on particle size, total antigen
concentration, and incubation time. Regarding incubation time, uptake of AgCPs by both
macrophages and BMDCs increased from 12 h to 24 h (Figure 14a, c). After 24 h, no significant
increase in antigen uptake was observed. Flow cytometry analysis revealed that 100% of
macrophages and BMDCs exposed to AgCPs produced a strong FITC signal indicating that
every cell had internalized some amount of AgCPs.
Regarding antigen concentration, antigen uptake by both macrophages and BMDCs
increased steadily up to the maximum total antigen concentration of 30 µg/ml (Figure 14b, d).
At lower concentrations, nearly all of the AgCPs co-incubated with macrophages were
internalized. As antigen concentration increased, uptake efficiency decreased for both cell types.
Macrophages were found to be more efficient at antigen uptake as they had phagocytosed 3- to
14-times as much AgCPs than did BMDCs.
Regarding particle size, maximum antigen uptake by macrophages was observed with
1m AgCPs (Figure 14b). Increasing particle size to 3µm reduced antigen uptake by
macrophages. Antigen uptake by BMDCs was independent of particle size up to 20 µg/ml
(Figure 14d). However, at 30 µg/ml concentration, BMDCs performed similarly to macrophages
in that maximum antigen uptake was observed with 1 µm AgCPs.

3.3.3. Macrophage activation
AgCPs outperformed soluble antigen in enhancing upregulation of antigen presenting
machinery, co-stimulatory and activation markers on macrophages. Specifically, up to 2-fold
increases in MHC I and CD80 expressions, up to a 3-fold increase in CD86 expression, and up to
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a 10-fold increase in CD80 expression were observed following APC exposure to AgCPs
compared to soluble antigens (Figure 15). Increases in MHC II and CD54 were also observed
albeit to a lesser degree (data not shown). Upregulation of all markers was dependent on AgCP
size with 1 µm AgCPs producing maximum responses.
In addition to higher activation status, CBA analyses revealed that macrophages coincubated with AgCPs released higher amounts of pro-inflammatory cytokines (Figure 16). IL-6
and MCP-1 secretions were more than doubled with 1 µm AgCPs compared to soluble antigen
while TNF- production increased by more than 70-fold. MIP-1 release was also modestly,
but significantly increased with AgCP co-incubation. IL-1β was not secreted by macrophages
exposed to soluble antigen but secreted at high levels with AgCPs co-incubation. Similar to
macrophage surface marker expression, cytokine release was dependent on AgCP size. IL-1
MCP-1 and IL-6 secretions were maximum with 1 µm AgCPs while TNF and MIP-1
responses were highest with 3µm AgCPs.

3.3.4. BMDC activation
Similar to the above studies with macrophages, AgCPs were more effective than soluble
antigen at enhancing upregulation of antigen presenting molecules, co-stimulatory molecules and
activation markers on BMDCs. Specifically, CD40 was increased by up to 5-fold, MHC I and
CD54 expressions were increased by up to 2-fold on BMDCs treated with AgCPs compared to
soluble antigens (Figure 17). To a lower degree, upregulation of MHC II and CD86 was also
observed (data not shown). The dependence of BMDC surface marker expression on AgCP size
showed a different pattern than was observed for macrophages. Maximum responses for CD40,
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CD80 and CD54 expressions were elicited by 300 nm AgCPs, whereas a slightly higher
expression of MHC I was produced by 1 µm AgCPs.
CBA analysis revealed that BMDCs co-incubated with AgCPs release greater levels of
pro-inflammatory cytokines (Figure 18). Secretions of IL-1β, IL-6, MCP-1, MIP-1 and TNF
were increased from 5- to more than 45-fold when BMDCs were co-incubated with AgCPs
rather than soluble antigen. For IL-1β and MCP-1, cytokine release was driven by the presence
of chitosan since CPs alone account for most, if not all, of the response. Particle size
significantly affected cytokine release for 4 of the 5 cytokines measured. Maximum MIP-1
release was achieved with 300nm AgCPs, maximum IL-6 and TNF- release with 1 µm AgCPs
while MCP-1 release was maximized with 3 µm AgCPs.

3.3.5. Antigen presentation by BMDCs
To investigate the effect of encapsulation on antigen presentation, OVA was encapsulated
in chitosan particles (OvaCPs) and co-incubated with BMDCs isolated from naïve C57BL/6J
mouse femer. The pulsed BMDCs were then co-cultured with CD4+ and CD8+ T-cells isolated
from the spleens of transgenic OT-II and OT-I mice respectively, to investigate whether BMDCs
pulsed with OvaCPs were capable of priming naive antigen-specific T-cells in vitro. BMDCs
pulsed with OvaCPs induced significantly higher levels of proliferation in CD4 + OT-II cells
compared to BMDCs pulsed with OVA antigen alone (Figure 19a). Furthermore, CD4+
proliferation increased significantly with the size of OvaCPs. BMDCs pulsed with 1 µm and 3
µm OvaCPs also induced significantly higher proliferative responses in CD8 + OT-I cells
compared to BMDCs pulsed with OVA257-264 peptide alone (Figure 19b). Once again, larger
particles resulted in greater proliferation.
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3.4. Discussion
The synthesis of chitosan nano- and microparticles to deliver drugs as well as
polypeptides has been reported previously [40, 116, 131, 153]. However, formulation
conditions, starting materials and resulting particle sizes vary considerably in the literature.
Because uptake of particles by APCs was found to be dependent on particle size [149, 150], it
was important to reproducibly synthesize AgCPs of discrete sizes to explore their effects on APC
function. Consequently, we developed a set of parameters, which when manipulated, could
reproducibly control chitosan particle size. SEM images and DLS data confirmed the formation
of AgCPs that were unimodal and well dispersed in aqueous medium. Zeta potential
measurements demonstrated that encapsulation of FITC-BSA significantly reduced the cationic
surface charge of similarly sized particles from +36.8 mV to +16.8 mV. This was expected
given that the pI of BSA is 4.7 and thus BSA carries an overall negative charge at neutral pH.
These data are similar to those of Gordon et al., who reported a reduction from +28.8 mV to
+18.3 mV when ovalbumin was adsorbed to the surfaces of chitosan nanoparticles [131]. The
fact that AgCPs retained a positive surface charge in our study likely facilitated uptake by APCs.
Previous research has shown that cationic particles interact with negatively charged cell
membranes thus encouraging endocytosis [149, 161].
Antigen encapsulation efficiency increased slightly with particle size as anticipated. The
high encapsulation efficiencies were consistent with values observed by others [114, 158]. It is
likely that the negative charge of BSA facilitated a high encapsulation rate by encouraging
interaction with polycationic chitosan. The effect of polypeptide charge on encapsulation
efficiency is the subject of ongoing research.
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Uptake studies demonstrated that particle size, concentration, and incubation time
influenced AgCP uptake by APCs (Figure 14). Maximum uptake of AgCPs by both
macrophages and dendritic cells was achieved by 24 h to 48 h of co-incubation. The decrease in
antigen uptake after 48 h may be explained by breakdown of antigen and a subsequent loss of
fluorescence signal from FITC-BSA.
For macrophages, AgCP uptake increased with particle size from 300 nm to 1 µm.
However, a further increase to 3 m, reduced antigen uptake. These data were in agreement with
previous studies which demonstrated that macrophage uptake reached a maximum with 1 µm
polystyrene particles with a similar positive surface charge [149, 162]. For BMDCs, antigen
uptake was independent of AgCP size until the highest concentration whereupon 1µm particles
were preferentially internalized. While it is not surprising that higher concentrations of AgCPs
resulted in higher levels of antigen uptake, it is noteworthy that the efficiency of uptake was
found to decrease with increasing AgCP concentration. For instance, at 1 g/ml AgCPs, nearly
all of the antigen could be detected in macrophages after 24 hours. However, at 30 g/ml, only
about 25-50% of antigen could be detected. These data indicate that uptake becomes saturated at
higher antigen concentrations.
As seen in Figures 15 and 17, AgCPs outperformed soluble antigen and unloaded CPs in
inducing the upregulation of antigen presenting molecules MHC I, MHC II as well as activation
and co-stimulatory markers CD40, CD80, and CD86. These markers in particular were chosen
as their upregulation is important for APC function during T-cell priming [163, 164]. The finding
that unloaded CPs caused modest increases in surface marker expression demonstrated that
chitosan itself may have modest immunostimulatory properties or that uptake of particles caused
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a phenotypic change. Additional studies in our lab are focused on defining the
immunomodulatory contributions of chitosan in vitro and in vivo.
Surface marker upregulation was more obvious with the macrophage cell line than with
BMDCs which likely contained multiple cell types at different stages of differentiation.
Nevertheless, these experiments demonstrated that delivery of encapsulated antigen provided an
additive or synergistic effect compared to either soluble antigens or unloaded CPs alone. Similar
to the uptake studies, macrophages responded most strongly to 1 µm AgCPs, while BMDCs
responded to all sizes more or less the same.
The enhanced activation status of APCs exposed to AgCPs was confirmed in cytokine
release studies. In both macrophages and BMDCs, AgCPs induced robust increases in production
of all pro-inflammatory cytokines tested: IL-1, IL-6, TNF-α, MCP-1 and MIP-1α. These
cytokines were selected based on their potential to induce inflammatory response subsequently
initiating antigen-specific immune responses. IL-1 helps stimulate helper T cells; IL-6 is a B
cell differentiation factor and a T cell activator; TNF-α induces T cell proliferation; MCP-1
induces chemotaxis of APCs; and MIP-1α is a granulocyte activator/chemokine and induces the
synthesis of other pro-inflammatory cytokines. Macrophages, not surprisingly, released greater
levels of monocyte/macrophage specific cytokines MCP-1 and MIP-1. BMDCs on the other
hand, produced much higher levels of IL-1and IL-6. In general, our results are consistent with
other studies showing that particulate antigens enhance inflammatory responses by APCs [94,
165].
Up to this point, our results had indicated that AgCPs outperformed soluble antigen in all
measures of APC activation. However, these findings would be futile if encapsulated antigens
were not appropriately processed and presented. To this end, the ability of BMDCs pulsed with
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OvaCPs to stimulate OVA-specific T cells was assessed. In accordance with our surface marker
and cytokine release studies, we found that BMDCs pulsed with OvaCPs induced significantly
higher OVA-specific CD4+ T-cell proliferation than BMDCs pulsed with soluble OVA protein.
Unlike the activation studies, the CD4+ T-cell proliferative response, and hence, BMDC antigen
presenting function increased with increasing AgCP size. It is possible that the higher
concentration of antigen per 3m particles outweighed any advantages of other AgCP sizes in
cytokine release or activation status.
Similarly, BMDCs pulsed with OvaCPs induced higher OVA-specific CD8+ T-cell
proliferation than BMDCs pulsed with OVA257-264 peptide. It should be noted that, while
BMDCs pulsed with peptide alone were effective at stimulating OVA-specific CD8+ T-cells in
vitro, peptides are rapidly degraded and highly inefficient without an delivery system in vivo.
Our planned studies will assess vaccine responses to AgCPs in vivo.
It is also worth noting that full length OVA protein was encapsulated in chitosan particles
for both CD4+ and CD8+ stimulation studies. Therefore, our findings indicate that encapsulated
OVA antigens were presented via both MHC I and II pathways. In fact, encapsulation of antigens
by chitosan particles may facilitate endosomal escape and cross presentation [166].

3.5. Conclusion:
In this specific aim, we demonstrated that chitosan particles are capable of efficiently
delivering encapsulated antigens and enhancing the activation status of both macrophages and
dendritic cells. In all measures of APC activation and presentation, AgCPs outperformed soluble
antigen. The ability of BMDC’s pulsed with AgCP to present both MHC I and MHC II epitopes
is particularly encouraging. Potential modifications of chitosan or incorporation of additional
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immune response modifiers underscore the versatility of this technology to enhance or control
vaccine responses. Our results indicate that AgCPs are a promising vaccine delivery platform
deserving of continued exploration. Specific aim 3 will evaluate the in vivo immune response to
chitosan particle-based antigen delivery systems.
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4. SPECIFIC AIM 3: Assess In Vivo Immunological Activity of Chitosan Particulate
Antigen Delivery System
4.1. Rationale
The studies performed in Specific Aim 2 determined the ability of the proposed systems
to activate APCs and enhance antigen presentation in vitro. However, this is only the first step in
assessing system efficacy. In this aim, chitosan particles are evaluated for their ability to induce
antigen specific vaccine response in vivo. Specifically, humoral and cell-mediate immune
response to the antigen are assessed.

4.2. Methodology
4.2.1. Reagents
Chitosan (viscosity 20-200, 200-600, and 600-1200 cPs degree of deacetylation 90%)
was purchased from Primex (Siglufjordur, Iceland) and purified via filtration in hydrochloric
acid and precipitation in sodium hydroxide. Pluronic F-68, acetic acid, sodium sulfate (Na2SO4),
L-glutamine, HEPES buffer, trypsin-EDTA, and ovalbumin (OVA) were purchased from Sigma
(St. Louis, MO). Concanavalin A (Con A) was purchased from Life Technologies (Green Island,
NY). Cell culture medium components including, fetal bovine serum (FBS), antibiotics,
Dulbecco's Modified Eagle Medium (DMEM), RPMI-1640, Alum adjuvant Imject-Alum, and
tetramethylbenzidine (TMB) substrate solution medium were purchased from Thermo Scientific
(Rockford, IL). Goat anti-mouse IgG, IgG1, and IgG2a antibodies were purchased from Southern
Biotech (Birmingham, AL).
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4.2.2. Mice
Female C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
Mice were housed in a pathogen-free animal facility and used at 8 to 10 weeks of age. All
experimental procedures were approved by the Institutional Animal Care and Use Committee at
the University of Arkansas and animal care was in compliance with The Guide for Care and Use
of Laboratory Animals (National Research Council).

4.2.3. Preparation of OVA loaded chitosan particles
Chitosan particles different sizes (300 nm, 1 µm, and 3 µm) encapsulating model antigen
OVA (OvaCPs) were prepared via precipitation-coacervation as described previously in Specific
Aim 1. Briefly, chitosan along with OVA was dissolved in 2% acetic acid solution. OvaCPs
were formed by adding 50mM salt solution drop wise to the chitosan solution using an infusion
pump (Pump 11 EliteTM, Harvard Apparatus, Holliston, MA). Nonionic stabilizer Pluronic F-68
was added and particles were allowed to stabilize for 2 hours under constant stirring and
intermittent sonication using a sonicator (S4000, Misonix, Farmingdale, NY). OvaCPs were
collected after centrifugation at 25,000 xg for 10min at 4°C and freeze dried (FreeZoneTM 2.5,
Labconco, Kansas city, MO) before further use. Particles of various sizes were obtained by
varying the formulation parameters as seen in Table 2.

4.2.4. Preparation of OVA loaded PLGA nanoparticles
PLGA nanoparticles encapsulating OVA antigen were prepared using a double emulsion
solvent evaporation method. Briefly, 3% PLGA solution was prepared by dissolving 90mg of
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PLGA (50/50) in 3ml of dichloromethane (DCM). OVA (2 mg) was dissolved in 200µl
deionized water, and this antigen solution was added to PLGA solution. The solution was then
sonicated for 30 seconds at 50W using a sonicator (S4000, Misonix, Farmingdale, NY) to obtain
the primary w/o emulsion. The emulsion solution was added drop wise into a 2% w/v PVA
solution, and the mixture was then sonicated for 2 minutes at 50W power to obtain a w/o/w
emulsion. After stirring overnight to allow solvent evaporation, PLGA nanoparticles were
collected through centrifugation, washed several times with DI water to remove residual PVA.
OVA loaded PLGA particles were than resuspended in deionized water and freeze dried
(FreeZone TM 2.5, Labconco, Kansas City, MO) before further use.

4.2.5. Characterization of OVA loaded PLGA nanoparticles
The size and size distribution of the nanoparticles were also determined by a Dynamic
Light Scattering method (Zetasizer Nano ZS90 TM, Malvern, Westborough, MA). OVA loading
efficiency was calculated indirectly. The amount of drug left in the supernatant after removing
the drug-loaded particles was determined using BCA protein assay. This amount was subtracted
from the initial concentration of drug to get the percentage of loading efficiency (Equation 3).

Percentage loading efficiency =

(Original conc−Supernatant conc)
Original conc

× 100

(3)

4.2.6. Immunization
Six groups of five 12 week old adult female C57BL/6J mice were immunized with OVA
delivered in 6 different formulations including 300 nm, 1 µm, or 3 µm OvaCPs, or OVA
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encapsulating PLGA nanoparticles with an effective antigen dose of 50 µg/mice. Vaccination
was done via sub-cutaneous injections. Separate cohorts of mice injected with OVA antigen
mixed with alum adjuvant served as controls. Each group was immunized twice within 2-weeks.
Four days after the final immunization, blood and spleens were collected aseptically.

4.2.7. OVA-specific antibody response
Four days after booster injection, blood from immunized mice was collected via
mandibular bleeding. Whole blood was allowed to clot for 1 hour at room temperature and
centrifuged at 2000g for 15 min for sera collection. Indirect enzyme-linked immunosorbent assay
(ELISA) was used for detection of anti-OVA-antibodies in the sera of immunized animals.
Briefly, 96 well plates were coated with 2 µg/ml OVA in 1 X PBS solution overnight at 4°C.
OVA coated wells were blocked with 5% BSA in PBS for 1 hour, and washed with PBS
containing 1% BSA. Serum samples from immunized mice were then added to plate and
incubated for 1 h at 37ºC. Wells incubated with mouse anti OVA IgG was used as positive
control while wells incubated with PBS acted as negative control. The washed plates were incubated with horseradish peroxidase-conjugated anti-mouse immunoglobulin (IgG) or anti-mouse
IgG1 or anti-mouse IgG2b. The plates were developed with TMB substrate solution and enzyme
neutralized with 3M HCl. The absorbance at 490 nm was read on a spectrophotometer (Synergy
2TM, BioTek, Winooski, VT).

4.2.8. Lymphocyte proliferation assay
Spleens obtained from immunized mice were crushed and passed through a 70 μm cell
strainer (BD Falcon, Bedford, MA). Red blood cells were lysed by using ACK lysis buffer and
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then resuspended in cell culture medium before further use. Irradiated splenocytes isolated from
naïve C57BL/6J mice (2.5 x 105 cells/well) were cultured in RPMI-1640 supplemented with 10%
FBS and pulsed with OVA in triplicate. The pulsed splenocytes acting as APCs were then coincubated with CD4+ T-cells (5 x 105 cells/well) isolated from immunized mice. After a 5 day
incubation, CD4+ T-cell proliferation in response to antigen stimulation was assessed by using
the CellTiter 96 kit (Promega, Madison, WI) according to the manufacturer’s instruction.
Irradiated splenocytes without any OVA or CD4+ T-cells alone were used as negative controls.
Irradiated splenocytes with CD4+ T-cells incubated for 72 hours with 1 µg/ml Con A were used
as a positive control.

4.3. Results
4.3.1. Effect of delivery system on OVA-specific antibody response
Antigen specific serum antibody assay was used to determine the ability of OvaCPs to
induce humoral response in immunized mice. Levels of anti-OVA antibodies in the sera
collected from immunized mice was determined using indirect ELISA. As seen in figure 21 and
22, both AgCPs and PLGA nanoparticles produced higher anti-OVA IgG and IgG1 antibodies
compared to both soluble OVA and alum-OVA. Compared to alum, immunization with OvaCPs
resulted higher serum antibodies with alum resulting in OD of 0.54 compared to 3.07 observed
with 1 µm OvaCPs. Also, OvaCPs influenced the humoral response against antigens with smaller
particles producing higher OVA specific IgG titers.
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4.3.2. Effect of delivery system on OVA-specific CD4+ proliferation
Lymphocyte proliferation assay was performed to determine the ability of OvaCPs to
induce a proliferative T cell responses. As seen in figure 22, significantly higher CD4 + T- cell
proliferation was observed with OvaCPs with three times higher cell proliferation observed with
OvaCPs compared to OVA delivered in PLGA and alum formulation. Immunization with PLGA
nanoparticles resulted in CD4+ to alum but lower than AgCPs of all sizes. However, no
difference was observed between 300 nm, 1 µm, and 3 µm AgCPs. Also, similar proliferation
was observed when comparing the Con A stimulated CD4+ T cells from all the groups indicating
comparable number of healthy CD4+ T cells that have ability to respond to a proliferation signal.

4.4. Discussion
Subunit antigens are rapidly degraded by proteases upon injection and generate neither
the antigen persistence nor immunostimulation required for the generation of robust antigenspecific immunity. As a result, a great deal of effort has been spent in evaluating delivery
systems that are capable of protecting subunit antigens and providing the appropriate stimulus to
generate antigen-specific immunity [167, 168]. In this specific aim, we have shown that
encapsulation of antigen in chitosan particles increases antigen specific immune response in vivo.
Others have investigated chitosan particle-based antigen delivery systems and showed that
antigen adsorbed onto the surface of chitosan particles was preserved and can elicit an immune
response [131]. However, absorption onto the particle surface is not ideal for polypeptide
antigen delivery as it exposes the antigens proteolytic enzymes causing rapid degradation.
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We found that encapsulation of antigens in particulate delivery systems, either chitosan
or PLGA particles, enhances the OVA-specific humoral response compared to the soluble OVA
or standard alum-adjuvanted OVA groups. This is consistent with other studies where
encapsulation of subunit antigens in particulate delivery systems have been shown to improve
antigen specific IgG production [169-171]. OvaCPs with mean sizes of 300 nm and 1 µm elicited
similar humoral responses as OVA-encapsulated PLGA nanoparticles. However, when the size
of OvaCPs was increased to 3 µm, OVA-specific antibody production decreased. These data are
consistent with published data showing that particle size affected humoral response with 2-70
µm particles eliciting significantly lower humoral immune response than submicron particles
[172, 173]. Nevertheless, data from the antibody response indicated that chitosan and PLGA
encapsulation produced similar antibody responses which were both markedly higher than the
alum formulation.
In contrast, lymphocyte proliferation assay demonstrated that OvaCPs were superior to
PLGA-OVA. PLGA-OVA elicited a response similar to that of alum which is consistent with
other studies where PLGA elicited strong cell mediated immune response to encapsulated
antigens similar to that of incomplete Freund's adjuvant (IFA) [171, 174]. Unlike the antibody
response, antigen specific CD4+ proliferation was not affected by AgCP size.
Additional studies are needed to understand the nature of the adaptive immune response
generated by OvaCPs. The finding that OvaCPs and PLGA were similar in antibody response but
superior in CD4+ proliferation indicated that chitosan encapsulation may facilitate a stronger Th1
response. Analyses of cytokines produced by in vitro stimulated CD4+ will better help define the
adaptive immune responses elicited by AgCPs.

59

4.5. Conclusion:
In this specific aim, we demonstrated that chitosan particles are capable of efficiently
delivering encapsulated antigens and enhancing adaptive immunity. In all measures of OvaCPs
outperformed soluble antigen and standard alum adjuvants. Compared to PLGA nanoparticles,
OvaCPs elicited much stronger CD4+ T-cell proliferation. Also, particle size influenced the serum
antibody secretion while showing minimal effect on CD4+ T cell proliferation. As such, our results
indicate that AgCPs are a promising vaccine delivery system that can aid in producing a robust
adaptive immune response towards encapsulated polypeptide antigens.
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5. CONCLUSIONS AND FUTURE DIRECTIONS
Particle-based vaccine delivery systems are under exploration to enhance antigen-specific
immunity against safe but poorly immunogenic subunit antigens. Chitosan is a promising
biomaterial for antigen encapsulation and delivery due to its ability form nano- and
microparticles in mild aqueous conditions thus preserving the antigenicity of loaded proteins. For
the first time, we have shown that chitosan particles properties including particle size, protein
loading efficiencies, and release parameters can be controlled by adjusting precipitation
coacervation parameters. As a result, we were able to study the effect of chitosan particle size on
antigen presenting function and in vivo efficacy. In vitro studies showed that AgCPs are
efficiently taken up by APCs which in turn become activated to present antigens via both MHC I
and MHC II pathways. Also, in vivo studies proved that AgCPs can elicit antigen-specific
immune responses and can do so more effectively than alum or PLGA nanoparticles. In short, we
have established chitosan particles as a promising, versatile antigen delivery system that can be
used to deliver subunit antigens for a wide variety of applications.
Looking ahead, there are a number of directions one can take to improve the efficacy of
AgCPs or further characterize chitosan-based antigen encapsulation. Regarding the former,
chitosan particles provide a tremendous opportunity for improving or modulating an adaptive
response through co-delivery of immunostimulatory compounds, such as poly I:C a TLR-3
agonist, and imiquimod, a TLR-7 agonist. The agonists would interact directly with APCs
including B-cells, macrophages, and dendritic cells through TLRs resulting in stronger APC
activation. APCs activated with TLR in the presence of antigen have the potential to generate
antigen specific immune responses.
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Furthermore, chitosan particles can be loaded with tumor associated antigens and used
for vaccination against tumors. For example, chitosan particles can be loaded with tyrosinase
related protein 2(TRP-2) which is overexpressed in melanoma cells for vaccination against
melanoma. Similarly, chitosan particles containing luteinizing hormone-releasing hormone
(LHRH) can be used for vaccination against breast, ovarian, and prostate cancer. Vaccination
using particulate antigens has several advantages over traditional cancer treatments involving
surgery, radiation, and chemotherapy. Most importantly, cancer vaccines have the potential to
generate tumor-specific immunity which protects cancer patients from recurrence. In general,
cancer vaccination is safer with fewer side effects
Chitosan particles may also encapsulate immunostimulatory cytokines such as GM-CSF,
IL-2, and IL-12 which have already demonstrated antitumor activity. Cytokines can be codelivered along with subunit antigens to enhance antigen specific immune responses. Another
strategy would be to inject chitosan particles encapsulating cytokines directly into solid tumors
and use a patient’s own tumor cells as the source of antigen. This allows for the development of
personalized medicine that can be used to induce a tumor specific response in any patient
irrespective of tumor phenotype.
Also, our studies have shown that the particles were taken up by APCs resulting in APC
activation and presentation of antigen with both MHC I and MHC II epitopes. However,
mechanisms involved in endosomal escape of antigen resulting in cross presentation of the MHC
I epitope were not understood. Chitosan may act as proton sponge that can burst lysosomes
resulting in antigen release into the cytosol. In the future, we can track intracellular trafficking
via confocal microscopy. Lysosomes can be labeled with pH sensitive dyes to co-localize
AgCPs. Antigens escaping lysosome will result in a diffuse fluorescence showing antigen release
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into the cytosol. Chitosan particles can be compared to PLGA particles which have no known
ability to escape lysosomes.
In addition, we have shown that chitosan particle properties can be controlled
systematically by varying formulation factors. However, we did not explore the effect of
interdependency between formulation factors on particle properties. As such, in the future,
comprehensive factorial analyses can be performed with factors including chitosan degree of
deacetylation, protein isoelectric point, solution volume, etc., that would take into account factor
interdependency. Full factorial analysis can be used to develop factorial equation (see equation
3) that can be used to determine parameters for formulation factors to obtain particles of required
properties. This equation can then be used to prepare chitosan particles of various sizes, protein
loading efficiencies, and release.
Particle parameters = A – B(X) – C(Y) + D (Z) – E (XY) – F (XZ) – G (YZ) + XYZ

(3)

Where X, Y, and Z represents formulation factor parameters; A, B, C, D, E, F, and G are
constants derived from factorial analysis.
The ability to scale up particle production is important for commercialization of chitosan
particle based antigen/protein delivery systems. We hypothesize that the concentration and
addition rate of precipitant salts can be adjusted to scale. For instance, to prepare 300 nm particle
using a 10 ml reaction setup, 1 ml of 1 M salt solution was added to chitosan solution at the rate
of 8 ml/min resulting in 100 mM final precipitant salt concentration in 7.5 sec. We hypothesize
that the time needed for the precipitant salt concentration to reach 100 mM is the critical factor in
controlling particle size. Using this hypothesis, 300 nm particles can be obtained from 1L system
by adding 10 ml of 10 M salt solution can be added at the rate of 1.3 ml/sec. Another approach
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would be to add 100 ml of 1 M salt solution at the rate of 13 ml/sec to obtain 300 nm particles.
As such, particles with similar properties might be obtained either by increasing initial
precipitant salt concentration or salt addition rate or both in proportion to reaction volume. It will
be interesting to see if the variation in precipitant salt concentration and addition rate influence
particle size.
Stability and storage of the particle is also important for commercialization. Protein
release studies showed that particles stored in non-ionic medium like deionized water retain most
of the encapsulated protein even after 2 weeks of incubation. However, further studies are
required to determine optimal storage conditions with minimal effect on the stability of chitosanprotein complexes. As such, protein release studies can be used to determine the stability of
chitosan particles over long periods of time when stored in non-ionic medium. Also, further
studies can be done to assess the limits of other storage methods including freeze drying in
maintaining chitosan particle stability and protein bioactivity. Briefly, chitosan particles stored
for various period of time up to12 months can be tested for encapsulation efficiency. Also, in
vitro bioactivity studies can be performed to determine the effect of storage conditions on
physiological function of the encapsulated proteins.
Our studies have shown that protein release properties of the particles depend on the
binding strength of proteins with strongly binding OVA being released from particles at much
slower rates compared to relatively weakly binding but similar sized BSA. As such, further
studies are required to understand the effect of chitosan and protein charge densities on particle
protein release. Chitosan molecular charge density can be controlled by varying the degree of
deacetylation or through functionalization of chitosan. Similarly, protein anionic charge density
can be modified through point mutations replacing positively charged amino acids like arginine
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or histidine or lysine with negatively charged amino acids including aspartic acid or glutamic
acid. A limiting factor in this strategy is that mutation of protein may affect the antigenicity and
even activity of protein. Ultimately, chitosan or protein molecules may be programmed to
facilitate slower or faster release of protein therapeutics.
Protein release studies showed that the type of precipitant salt used influences the rate of
protein release. Particles prepared using salts with high hydrating strength releasing protein at
higher rate compared to particles prepared using salts with lower hydrating strength. The
mechanism of action is not clear given that protein release experiments were all performed in
PBS. It is possible that small quantities of precipitant salts might persist within particle
complexes thus influencing the interaction between chitosan and protein. The presence of
precipitant salts within the particles can be tested using mass spectrometry. Another potential
reason for the variation in protein release might be that precipitant salts influence the porosity of
particles during particle formation and therefore the subsequent protein release. Further studies
may explore the effect of precipitant salt on porosity by measuring porosity of resultant particles
using scanning electron microscopy (SEM) and volumetric analysis to measure the change in
volume of hydrated particles compared to dry samples.
Non-ionic pluronic was used as a surfactant for preparation of chitosan particles given
pluronic’s inability to interact with chitosan particles ionotropically. However, small quantities
of pluronic might be trapped within the particle complex and influence particle properties. We do
not suspect that the amount of pluronic present in the particles is detrimental to cells as no cell
death was observed in our in vitro studies. Nevertheless it is useful to quantify the amount of
pluronic present. A colorimetric assay involving the interaction of pluronic with cobalt
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thiocynate can be used to quantify pluronic by measuring the absorbance of the complex at 328
nm. Also, the effect of pluronic contamination on chitosan particle properties can be determined.
In summary, we have established that chitosan particle properties can be controlled by
varying formulation parameters. However, further work is required to standardize chitosan
particle preparation protocols for commercial use. Also, we have shown that chitosan particles
are capable of inducing antigen specific immune response towards encapsulate antigens.
However, we have only scratched the surface of this promising platform with further studies
required to realize the true potential of chitosan particles as vaccine and immunotherapy delivery
systems.
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Table. 1. Effect of formulation factors on particle size, polydispersity index (PDI) and protein
loading efficiency; *Data are presented as mean ± standard deviation for three independent
experiments. ** No particle formation. a Viscosity range of chitosan was indicated by
manufacturer as obtained at a concentration of 1 mg/ml (w/v) in 1% acetic acid

Na2SO4
(NH4)2SO4

Mean Size*
(nm)
427 ± 7.6
551.9 ± 3.5

0.113
0.135

Loading
Efficiency*
54.0 ± 2.6
62.5 ± 6.1

MgSO4

445 ± 7.7

0.124

47.5 ± 2

Na3C6H5O7

490 ± 18.3

0.154

83.7 ± 3.5

Na3PO4

1621 ± 188

0.667

14.6 ± 1.7

NaCl

-**

-

-

<20 cPs
20-200 cPs

418 ± 16.2
424 ± 7.7

0.104
0.160

50.3 ± 2.3
56.5 ± 3.4

200-600 cPs

605 ± 13.3

0.190

56.5 ± 2.6

600-1200 cPs

728 ± 15

0.212

53.5 ± 4.3

1200-2000 cPs

854 ± 26.2

0.385

58.5 ± 4.2

0.5 mg/ml
1 mg/ml

334 ± 27.5
418 ± 3.5

0.093
0.113

58.5 ± 3.4
57.3 ± 2.5

2 mg/ml

521 ± 2.8

0.259

59.9 ± 6.8

3 mg/ml

587 ± 10.6

0.182

73.6 ± 2.2

5 mg/ml

656 ± 13.6

0.277

92 ± 0.8

0W
10 W

922 ± 79.2
438 ± 3.9

0.657
0.182

92.3 ± 1.8
88.3 ± 5.3

20 W

418 ± 9.6

0.156

74.2 ± 6.3

40 W

421 ± 4.1

0.098

56.5 ± 2.6

0.2 ml/min
1 ml/min

774 ± 33.2
574 ± 9.1

0.580
0.351

71.9 ± 7
67.3 ± 3.2

3 ml/min

495 ± 3.6

0.250

65.3 ± 3.6

5 ml/min

444 ± 5.6

0.210

62 ± 2.8

8 ml/min

424 ± 2.1

0.121

58.1 ± 2.2

Insulin

411 ± 19.3

0.195

98.3 ± 0.5

Ova

423 ± 3.6

0.178

96.5 ± 1.1

BSA

424 ± 7.7

0.160

58.1 ± 2.5

Con A

410 ± 5.5

0.113

53.5 ± 3.6

Factor

Precipitant salt

Chitosan Viscositya
(molecular weight)

Chitosan
Concentration

Sonication power

Precipitant addition
rate

Protein

Run
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PDI

Table 2: Experimental design for protein release studies: Effect of particle size. Data are
presented as mean ± standard deviation for three independent experiments.
Particle
group

Chitosan
conc

Precipitant
salt

Protein

Salt
addition
rate

Mean Size
(nm)

300nm

0.5 mg/ml

Na2SO4

8 ml/min

318.2±11

1µm

3 mg/ml

Na2SO4

1 ml/min

1133±54.1

83.5±8.3

3µm

5 mg/ml

Na2SO4

FITCBSA
FITCBSA
FITCBSA

Protein
loading
efficiency
(%)
58.1±3.7

0.2 ml/min

2871±216

96.6±0.6
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Table 3: Experimental design for protein release studies: Effect of precipitant salt composition.
Data are presented as mean ± standard deviation for three independent experiments.
Particle
group

Chitosan
conc

Precipitant
salt

Protein

Salt
addition
rate

Mean
Size
(nm)

Na2SO4

1 mg/ml

Na2SO4

8 ml/min

448±12

(NH4)2SO4

1 mg/ml

(NH4)2SO4

8 ml/min

561±3.4

62±5.3

MgSO4

1 mg/ml

MgSO4

8 ml/min

462±6.3

54.3±3.4

Na3C6H5O7

1 mg/ml

Na3C6H5O7

8 ml/min

478±64.3

86±2.1

Na3PO4

1 mg/ml

Na3PO4

FITCBSA
FITCBSA
FITCBSA
FITCBSA
FITCBSA

Protein
loading
efficiency
(%)
56.4±6.3

8 ml/min

1423±156

14.3±6.6
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Table 4: Experimental design for protein release studies: Effect of protein molecular weight.
Data are presented as mean ± standard deviation for three independent experiments.
Particle
group

Chitosan
conc

Precipitant
salt

Protein

Salt
addition
rate

FITCInsulin
FITCOVA
FITCBSA
FITCCon A

1 mg/ml

Na2SO4

FITC-Insulin

8 ml/min
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Figure. 1. Schematic representation of viral vector particle constituting carrier viral protein
envelope and antigen genetic material.
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Figure. 2. Schematic representation of virus like particle delivery system.
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Figure. 3. Schematic representation of multi-layered liposomal particle encompassing both
antigen and viral capsids acting as immunopotentiators.
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Figure. 4. Schematic representation of ISCOM with hydrophobic antigen loaded into the
phospholipid/cholesterol cage.
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Figure. 5. Schematic representation of non-degradable nano/micoparticle vaccine delivery
system; Particle can be designed to carry antigens while particle itself acts as an adjuvant or have
adjuvant conjugated along with antigen.
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Figure. 6. Schematic representation of degradable polymeric particle; Particle can be designed to
carry antigens while particle itself acts as an adjuvant or have adjuvant conjugated along with
antigen.
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x

y

Figure. 7. Chemical structure of chitosan. Chitosan is an unbranched copolymer of Nacetylglucosamine (x) and glucosamine (y) units linked by β(1-4) glycosidic bonds where the
ratio of y to x is greater than 1.5.
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Figure. 8. Effect of precipitation-coacervation parameters on chitosan-FITC-BSA particle size
and PDI. Parameters including: chitosan concentration, molecular weight/viscosity, precipitant
salt addition rate, and sonication power were varied following the experimental design described
in Table 1. Resultant particle size and PDI of the resultant particles were determined by DLS.
Data are presented as mean ± standard deviation of three independent experiments.
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Figure. 9. Effect of salinity of release medium on protein release; Particles prepared using
precipitant salt Na2SO4 encapsulating model protein FITC-BSA are incubated with 0.1X, 0.5X, 1
X PBS. Particles incubated in deionized water (DI water) served as negative control. Samples
were collected at each time point and protein release was quantified by measuring fluorescence
via fluorescence spectroscopy. Cumulative protein release was calculated by adding the protein
released at each individual time point.
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Figure. 10. Morphology and size distribution of AgCPs. Representative SEM images and DLS
data show that 300 nm AgCPs, 1 μm AgCPs, and 3 μm AgCPs, are unimodally distributed and
spherical to elliptical with porous non-uniform structures.
80

60

% Cumulatve Release

50
40
30
300nm

20

1µm
3µm

10
0
0

50

100
Incubation Time (hours)

150

200

Figure. 11. Effect of chitosan particle size on protein release; 300nm, 1 µm, and 3 µm CPs
encapsulating model protein FITC-BSA were incubated with PBS. Samples were collected at
each time point and protein release was quantified by measuring fluorescence via fluorescence
spectroscopy. Cumulative protein release was calculated by adding the protein release at each
individual time point.
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Figure. 12. Effect of ionic strength of precipitating salt on protein release; Particles prepared
using hofmeister series ionic precipitant salts Na2SO4, (NH4)2SO4, MgSO4, Na3C6H5O7, and
Na3PO4 encapsulating model protein FITC-BSA were incubated with PBS. Samples were
collected at each time point and protein release was quantified by measuring fluorescence via
fluorescence spectroscopy. Cumulative protein release was calculated by adding the protein
release at each individual time point.
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Figure.13. Effect of encapsulated protein size on protein release by particles; Particles
encapsulating model proteins FITC-Insulin, FITC-OVA, FITC-BSA, and FITC-Con A were
incubated with PBS. Samples were collected at each time point and protein release was
quantified by measuring fluorescence via fluorescence spectroscopy. Cumulative protein release
was calculated by adding the protein release at each individual time point.
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Figure. 14. Effect of size, concentration, and incubation time on uptake of AgCPs by APCs. (a)
RAW 264.7 macrophages or (c) BMDCs were co-incubated with 1µm AgCPs at an effective
antigen/FITC-BSA concentration of 30 µg/ml for 12, 24, or 48 h. (b) RAW 264.7 macrophages
or (d) BMDCs were co-incubated with 300nm, 1µm, or 3µm AgCPs at effective antigen
concentrations of 1, 5, 10, 20, or 30 µg/ml for 24 h. After each co-incubation, cells were rinsed
three times with PBS and lysed with 1% triton solution. The amount of FITC-BSA released was
quantified via fluorescence spectroscopy. Data are presented as mean ± standard deviation from
three independent experiments. *p ≤ 0.05 vs. 12 h incubation; **p ≤ 0.05 comparing AgCP
sizes for a particular antigen concentration.
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Figure. 15. Surface marker expression by RAW 264.7 macrophages following exposure to
soluble antigen, CPs without antigen or AgCPs. Macrophages were co-incubated with soluble or
particulate antigens at a final antigen concentration of 30 µg/ml. After 24 h, cells were rinsed
three times, harvested, blocked with purified anti-mouse CD16/CD32 and stained with
fluorescence-labeled antibodies to MHC molecules and activation markers (solid lines). Filled
histograms represent cells treated with medium alone. Dotted line histograms are treated cells
stained with appropriate isotype controls. All histograms are from one representative experiment
of three independent experiments producing similar results. Panel numbers indicate the mean
percentages of positive cells (top number) and mean fluorescence intensities (bottom number) of
respective samples.
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Figure. 16. Cytokine release by RAW 264.7 macrophages. Cells were co-incubated with
soluble or particulate antigens at a final antigen concentration of 30 µg/ml. After 24 h,
supernatants of all groups were collected and analyzed for cytokine production using a
customized CBA flex set. Data are presented as mean ± standard deviation from three
independent experiments. *p ≤ 0.05 vs. soluble antigen (FITC-BSA); ** p ≤ 0.05 vs. other sizes
of AgCPs.
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Figure. 17. Surface marker expression by BMDCs following exposure to soluble antigen, CPs
without antigen or AgCPs. Macrophages were co-incubated with soluble or particulate antigens
at a final antigen concentration of 30 µg/ml. After 24 h, cells were rinsed three times, blocked
with purified anti-mouse CD16/CD32 and stained with fluorescence-labeled antibodies to MHC
molecules and activation markers (solid lines). Filled histograms represent cells treated with
medium alone. Dotted line histograms are treated cells stained with appropriate isotype controls.
All histograms are from one representative experiment of three independent experiments
producing similar results. Panel numbers indicate the mean percentages of positive cells (top
number) and mean fluorescence intensities (bottom number) of respective samples.
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Figure. 18. Cytokine release by BMDCs. Cells were co-incubated with soluble or particulate
antigens at a final antigen concentration of 30 µg/ml. After 24 h, supernatants of all groups were
collected and analyzed for cytokine production using a customized CBA flex set. Data are
presented as mean ± standard deviation from three independent experiments. *p ≤ 0.05 vs.
soluble antigen (FITC-BSA); ** p ≤ 0.05 vs. other sizes of AgCPs.
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Figure. 19. Proliferation of (a) OVA-specific CD4+ T-cells, and (b) OVA-specific CD8+ T-cells
in response to presentation of antigen by BMDCs. BMDCs were pulsed with CPs, AgCPs,
soluble full length OVA or the MHC I-restricted OVA257-264 peptide for 24 h and then coincubated with CD4+ or CD8+ T-cells from OT-II or OT-I mice, respectively. After 72 h, T cell
proliferation was determined via a non-radioactive proliferation assay (CellTiter Glo; Promega,
Madison, WI). Data are presented as mean relative light unit (RLU) ± standard deviation from
one of two independent experiments with similar results. *p ≤ 0.05 vs. OVA or OVA peptide;
**p ≤ 0.05 vs other AgCP sizes.
89

4.5
4

Srum IgG (OD)

3.5
3
2.5
2
1.5
1
0.5
0
PBS OVA AlumOVA PLGA nps 300 nm
AgCPs

1 µm
AgCPs

3 µm
AgCPs

Figure. 20. Serum anti-OVA IgG antibodies. Adult C57BL/6J mice were immunized two weeks
apart with one of six vaccines: OVA alone, OVA formulated with alum, PLGA-OVA, 300 nm, 1
µm, and 3 µm OvaCPs. Sera were collected five days after booster injection and analyzed using
ELISA. Mouse anti-OVA antibodies were used as positive controls with PBS acting as negative
control. The data represent the mean ± standard deviation of two independent immunization
experiments (n = 10, 5 mice per vaccine x 2).
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Figure. 21. Serum anti-OVA IgG1 antibodies. Adult C57BL/6J Mice were immunized two
weeks apart with one of six vaccines: OVA alone, OVA formulated with alum, PLGA-OVA, 300
nm, 1 µm, and 3 µm OvaCPs. Sera were collected five days after booster injection and analyzed
using ELISA. Mouse anti-OVA antibodies were used as positive controls with PBS acting as
negative control. The data represent the mean ± standard deviation of two independent
immunization experiments (n = 10, 5 mice per vaccine x 2).
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Figure. 22. (a) Proliferation of CD4+ T-cells isolated from immunized mice. Adult C57BL/6J
Mice were immunized two weeks apart with one of six vaccines: OVA alone, OVA formulated
with alum, PLGA-OVA, 300 nm, 1 µm, and 3 µm OvaCPs. Five days post-booster injection.
CD4+ T-cells from individual mice were isolated from immunized mice spleens and co-cultured
with irradiated splenocytes isolated from naïve mice pulsed with OVA. (b) Cells stimulated with
Con A served as the positive controls. The data represent the mean ± standard deviation of two
independent immunization experiments (n = 10, 5 mice per vaccine x 2).
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